View Filing Data

Print Document View Excel Document

DOCUMENT AND ENTITY INFORMATION - USD ($)	12 Months Ended
DOCUMENT AND ENTITY INFORMATION - USD ($)	Mar. 28, 2015	Apr. 25, 2015	Sep. 27, 2014
Document And Entity Information [Abstract]
Entity Registrant Name	HAEMONETICS CORP
Entity Central Index Key	0000313143
Current Fiscal Year End Date	--03-28
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Mar. 28, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		51,682,698
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 1,777,275,792

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Income Statement [Abstract]
Net revenues	$ 910,373	$ 938,509	$ 891,990
Cost of goods sold	475,955	470,144	463,859
Gross profit	434,418	468,365	428,131
Operating expenses:
Research and development	54,187	54,200	44,394
Selling, general and administrative	334,250	366,022	323,053
Asset write-down	5,441	1,711	4,247
Total operating expenses	393,878	421,933	371,694
Operating income	40,540	46,432	56,437
Other (expense) income, net	(9,375)	(10,031)	(6,540)
Income before provision for income taxes	31,165	36,401	49,897
Provision for income taxes	14,268	1,253	11,097
Net income	$ 16,897	$ 35,148	$ 38,800
Net income per share - basic (in dollars per share)	$ 0.33	$ 0.68	$ 0.76
Net income per share - diluted (in dollars per share)	$ 0.32	$ 0.67	$ 0.74
Weighted average shares outstanding
Basic (in shares)	51,533	51,611	51,349
Diluted (in shares)	52,089	52,377	52,259

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Statement of Comprehensive Income [Abstract]
Net income	$ 16,897	$ 35,148	$ 38,800
Other comprehensive loss:
Impact of defined benefit plans, net of tax	(4,331)	481	(820)
Foreign currency translation adjustment	(23,710)	(935)	(4,705)
Unrealized gain on cash flow hedges, net of tax	11,371	5,001	4,594
Reclassifications into earnings of cash flow hedge gains, net of tax	(6,464)	(8,570)	(2,746)
Other comprehensive loss	(23,134)	(4,023)	(3,677)
Comprehensive (loss) income	$ (6,237)	$ 31,125	$ 35,123

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 28, 2015	Mar. 29, 2014
Current assets:
Cash and cash equivalents	$ 160,662	$ 192,469
Accounts receivable, less allowance of $1,749 at March 28, 2015 and $1,676 at March 29, 2014	145,827	164,603
Inventories, net	211,077	197,661
Deferred tax asset, net	12,608	14,144
Prepaid expenses and other current assets	40,103	54,099
Total current assets	570,277	622,976
Property, plant and equipment, net	321,948	271,437
Intangible assets, net	244,588	271,159
Goodwill	334,310	336,768
Deferred tax asset, long term	3,023	1,184
Other long-term assets	11,271	10,654
Total assets	1,485,417	1,514,178
Current liabilities:
Notes payable and current maturities of long-term debt	21,522	45,630
Accounts payable	48,425	53,562
Accrued payroll and related costs	51,115	54,913
Accrued taxes	3,819	3,113
Other current liabilities	64,211	59,710
Total current liabilities	189,092	216,928
Long-term debt, net of current maturities	406,369	392,057
Long-term deferred tax liability	32,097	29,664
Other long-term liabilities	31,737	37,641
Stockholders’ equity:
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 51,670,969 shares at March 28, 2015 and 52,041,189 shares at March 29, 2014	517	520
Additional paid-in capital	426,964	402,611
Retained earnings	420,365	433,347
Accumulated other comprehensive (loss) income	(21,724)	1,410
Total stockholders’ equity	826,122	837,888
Total liabilities and stockholders’ equity	$ 1,485,417	$ 1,514,178

CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($) $ in Thousands	Mar. 28, 2015	Mar. 29, 2014
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 1,749	$ 1,676
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	51,670,969	52,041,189
Common stock, outstanding (in shares)	51,670,969	52,041,189

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income/(Loss)
Balance, value at Mar. 31, 2012	$ 732,631	$ 506	$ 322,232	$ 400,783	$ 9,110
Balance, shares (in shares) at Mar. 31, 2012		50,604
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan	4,142	$ 1	4,141
Employee stock purchase plan (in shares)		151
Exercise of stock options and related tax benefit	35,815	$ 14	35,801
Exercise of stock options and related tax benefit (in shares)		1,398
Stock-based compensation adjustment related to acquisition	504		504
Shares repurchased	(50,003)	$ (12)	(8,607)	(41,384)
Shares repurchased (in shares)		(1,236)
Issuance of restricted stock, net of cancellations	1	$ 1
Issuance of restricted stock, net of cancellations (in shares)		115
Stock compensation expense	10,969		10,969
Net income	38,800
Other comprehensive loss	(3,677)
Balance, value at Mar. 30, 2013	769,182	$ 510	365,040	398,199	5,433
Balance, shares (in shares) at Mar. 30, 2013		51,032
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan	5,229	$ 2	5,227
Employee stock purchase plan (in shares)		161
Exercise of stock options and related tax benefit	19,270	$ 7	19,263
Exercise of stock options and related tax benefit (in shares)		740
Issuance of restricted stock, net of cancellations	1	$ 1
Issuance of restricted stock, net of cancellations (in shares)		108
Stock compensation expense	13,081		13,081
Net income	35,148
Other comprehensive loss	(4,023)
Balance, value at Mar. 29, 2014	837,888	$ 520	402,611	433,347	1,410
Balance, shares (in shares) at Mar. 29, 2014		52,041
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan	4,763	$ 2	4,761
Employee stock purchase plan (in shares)		183
Exercise of stock options and related tax benefit	14,645	$ 5	14,640
Exercise of stock options and related tax benefit (in shares)		500
Shares repurchased	(39,033)	$ (11)	(9,143)	(29,879)
Shares repurchased (in shares)		(1,174)
Issuance of restricted stock, net of cancellations	1	$ 1
Issuance of restricted stock, net of cancellations (in shares)		121
Stock compensation expense	14,095		14,095
Net income	16,897
Other comprehensive loss	(23,134)
Balance, value at Mar. 28, 2015	$ 826,122	$ 517	$ 426,964	$ 420,365	$ (21,724)
Balance, shares (in shares) at Mar. 28, 2015		51,671

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Cash Flows from Operating Activities:
Net income	$ 16,897	$ 35,148	$ 38,800
Non-cash items:
Depreciation and amortization	86,053	81,740	65,481
Amortization of financing costs	1,013	1,505	1,139
Stock compensation expense	14,095	13,081	10,969
Deferred tax expense	4,230	(202)	589
Purchased in process research and development	0	3,569	0
Loss on sale of property, plant and equipment	42	293	351
Unrealized (gain)/loss from hedging activities	1,558	(128)	700
Changes in fair value of contingent consideration	(2,918)	45	0
Asset write-down	5,877	2,587	4,247
Change in operating assets and liabilities:
Decrease/(increase) in accounts receivable, net	8,835	6,154	(38,080)
Increase in inventories	(16,932)	(12,684)	(18,685)
(Increase)/decrease in prepaid income taxes	10,662	1,175	(4,025)
Decrease/(increase) in other assets and other long-term liabilities	(8,013)	3,176	(6,187)
Tax benefit of exercise of stock options	3,786	1,649	4,194
Increase in accounts payable and accrued expenses	1,993	2,416	25,581
Net cash provided by operating activities	127,178	139,524	85,074
Cash Flows from Investing Activities:
Capital expenditures on property, plant and equipment	(122,220)	(73,648)	(62,188)
Proceeds from sale of property, plant and equipment	452	488	1,968
Acquisition of Whole Blood Business	0	0	(535,175)
Acquisition of Hemerus	0	(23,124)	(1,000)
Other acquisitions	0	(9,546)	0
Net cash used in investing activities	(121,768)	(105,830)	(596,395)
Cash Flows from Financing Activities:
Payments on long-term real estate mortgage	(1,048)	(964)	(886)
Net (decrease)/increase in short-term loans	843	(5,521)	7,446
Term loan borrowings	0	0	475,000
Payments on long-term real estate mortgage	(8,531)	(37,063)	0
Debt issuance costs	(1,013)	0	(5,467)
Proceeds from employee stock purchase plan	4,763	5,229	4,142
Proceeds from exercise of stock options	9,290	15,224	27,517
Excess tax benefit on exercise of stock options	1,569	2,395	4,101
Share repurchase	(39,033)	0	(50,000)
Net cash (used in)/provided by financing activities	(33,160)	(20,700)	461,853
Effect of exchange rates on cash and cash equivalents	(4,057)	355	(273)
Net Increase/(Decrease) in Cash and Cash Equivalents	(31,807)	13,349	(49,741)
Cash and Cash Equivalents at Beginning of Year	192,469	179,120	228,861
Cash and Cash Equivalents at End of Year	160,662	192,469	179,120
Non-cash Investing and Financing Activities:
Transfers from inventory to fixed assets for placement of Haemonetics equipment	7,458	10,584	21,677
Supplemental Disclosures of Cash Flow Information:
Interest paid	8,497	8,942	5,910
Income taxes paid	$ 11,211	$ 7,261	$ 13,178

DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION	12 Months Ended
DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION	Mar. 28, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION	DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION Haemonetics is a global healthcare company dedicated to providing innovative blood management solutions for our customers — plasma collectors, blood collectors, and hospitals. Anchored by our strong brand name in medical device systems for the transfusion industry, we also provide information technology platforms and value added services to provide customers with business solutions which support improved care for patients and efficiency in the blood supply chain. Our systems automate the collection and processing of donated blood; perform blood diagnostics; salvage and process surgical patient blood; and dispense blood within the hospital. These systems include devices and single-use, proprietary disposable sets that operate only on our specialized equipment. Our manual blood collection and filtration systems enable the manual collection of all blood components while detecting bacteria, thus reducing the risks of infection through transfusion. Our blood processing systems allow users to collect and process only the blood component(s) they target — plasma, platelets, or red blood cells — increasing donor and patient safety as well as collection efficiencies. Our blood diagnostics system assesses the likelihood of a patient’s blood loss allowing clinicians to make informed decisions about a patient’s treatment as it relates to blood loss in surgery. Our surgical blood salvage systems collect blood lost by a patient in surgery, clean the blood, and make it available for reinfusion to the patient, in this way giving the patient the safest blood possible — his or her own. Our blood distribution systems are “smart” refrigerators located throughout hospitals which automate the storage, inventory tracking, and dispositioning of blood in key blood use areas. Our information technology platforms are used by blood and plasma collectors to improve the safety and efficiency of blood collection logistics by eliminating previously manual functions at not-for-profit blood centers and commercial plasma centers which are operated by our bio-pharmaceutical customers. Our platforms are also used by hospitals to enable hospital administrators to monitor and measure blood management practices and to manage processes within transfusion services. Our information technology platforms allow all customers to better manage processes across the blood supply chain, comply with regulatory requirements, and identify increased opportunities to reduce costs. On November 30, 2012 we completed a two-for-one split of our common stock in the form of a stock dividend. Unless otherwise indicated, all common stock shares and per share information referenced within the Consolidated Financial Statements have been retroactively adjusted to reflect the stock split. The exercise price of each outstanding option has also been proportionately and retroactively adjusted for all periods presented. Par value per share and authorized shares were however not affected by the stock split. The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The accompanying consolidated financial statements present separately our financial position, results of operations, cash flows, and changes in shareholders’ equity. All amounts presented, except per share amounts, are stated in thousands of U.S. dollars, unless otherwise indicated. We consider events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated, and there were no material items that arose after the balance sheet date but prior to the issuance of the financial statements that would be considered recognized subsequent events.

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS

12 Months Ended

Mar. 28, 2015

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Fiscal Year

Our fiscal year ends on the Saturday closest to the last day of March. Fiscal years 2015, 2014 and 2013 each includes 52 weeks with each quarter having 13 weeks.

Principles of Consolidation

The accompanying consolidated financial statements include all accounts including those of our subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could vary from the amounts derived from our estimates and assumptions.

Reclassifications

Certain reclassifications have been made to prior years' amounts to conform to the current year's presentation.

Contingencies

We may become involved in various legal proceedings that arise in the ordinary course of business, including, without limitation, patent infringement, product liability and environmental matters. Accruals recorded for various contingencies including legal proceedings, self-insurance and other claims are based on judgment, the probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarially determined estimates. When a range is established but a best estimate cannot be made, we record the minimum loss contingency amount. These estimates are often initially developed substantially earlier than the ultimate loss is known, and the estimates are reevaluated each accounting period, as additional information is available. When we are initially unable to develop a best estimate of loss, we record the minimum amount of loss, which could be zero. As information becomes known, additional loss provision is recorded when either a best estimate can be made or the minimum loss amount is increased. When events result in an expectation of a more favorable outcome than previously expected, our best estimate is changed to a lower amount.

Revenue Recognition

Our revenue recognition policy is to recognize revenues from product sales, software and services in accordance with ASC Topic 605, Revenue Recognition, and ASC Topic 985-605, Software. These standards require that revenues are recognized when persuasive evidence of an arrangement exists, product delivery, including customer acceptance, has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. We may have multiple contracts with the same customer and each contract is typically treated as a separate arrangement. When more than one element such as equipment, disposables, and services are contained in a single arrangement, we allocate revenue between the elements based on each element’s relative selling price, provided that each element meets the criteria for treatment as a separate unit of accounting. An item is considered a separate unit of accounting if it has value to the customer on a stand-alone basis. The selling price of the undelivered elements is determined by the price charged when the element is sold separately, or in cases when the item is not sold separately, by third-party evidence of selling price or by management's best estimate of selling price. For our software arrangements accounted for under the provisions of ASC 985-605, Software, we establish fair value of undelivered elements based upon vendor specific objective evidence.

Product Revenues

Product sales consist of the sale of our disposable blood component collection and processing sets and the related equipment. On product sales to end customers, revenue is recognized when both the title and risk of loss have transferred to the customer as determined by the shipping terms and all obligations have been completed. For product sales to distributors, we recognize revenue for both equipment and disposables upon shipment of these products to our distributors. Our standard contracts with our distributors state that title to the equipment passes to the distributors at point of shipment to a distributor’s location. The distributors are responsible for shipment to the end customer along with installation, training and acceptance of the equipment by the end customer. Payments from distributors are not contingent upon resale of the product.

Software Revenues

Our software solutions business provides support to our plasma, blood collection and hospital customers. We provide information technology platforms and technical support for donor recruitment, blood and plasma testing laboratories, and for efficient and compliant operations of blood and plasma collection centers. For plasma customers, we also provide information technology platforms for managing distribution of plasma from collection centers to plasma fractionation facilities. For hospitals, we provide solutions to help improve patient safety, reduce cost and ensure compliance.

Our software solutions revenues also include revenue from software sales which includes per collection or monthly subscription fees for the license and support of the software as well as hosting services. A significant portion of our software sales are perpetual licenses typically accompanied with significant implementation service fees related to software customization as well as other professional and technical service fees.

We generally recognize revenue from the sale of perpetual licenses on a percentage-of-completion basis which requires us to make reasonable estimates of the extent of progress toward completion of the contract. These arrangements most often include providing customized implementation services to our customer. We also provide other services, including in some instances hosting, technical support, and maintenance, for the payment of periodic, monthly, or quarterly fees. We recognize these fees and charges as earned, typically as these services are provided during the contract period.

Non-Income Taxes

We are required to collect sales or valued added taxes in connection with the sale of certain of our products. We report revenues net of these amounts as they are promptly remitted to the relevant taxing authority.

We are also required to pay a medical device excise tax relating to U.S. sales of Class I, II and III medical devices. This excise tax went into effect January 1, 2013, established as part of the March 2010 U.S. healthcare reform legislation, and has been included in selling, general and administrative expenses.

Translation of Foreign Currencies

All assets and liabilities of foreign subsidiaries are translated at the rate of exchange at year-end while sales and expenses are translated at an average rate in effect during the year. The net effect of these translation adjustments is shown in the accompanying financial statements as a component of stockholders' equity. Foreign currency transaction gains and losses, including those resulting from inter-company transactions, are charged directly to earnings and included in other (expense) income, net on the consolidated statements of income. The impact of foreign exchange on long-term intercompany loans, for which repayment has not been scheduled or planned, are recorded in accumulated other comprehensive income on the consolidated balance sheet.

Cash and Cash Equivalents

Cash equivalents include various instruments such as money market funds, U.S. government obligations and commercial paper with maturities of three months or less at date of acquisition. Cash and cash equivalents are recorded at cost, which approximates fair market value. As of March 28, 2015, our cash and cash equivalents consisted of investments in United States Government Agency and institutional money market funds.

Allowance for Doubtful Accounts

We establish a specific allowance for customers when it is probable that they will not be able to meet their financial obligation. Customer accounts are reviewed individually on a regular basis and appropriate reserves are established as deemed appropriate. We also maintain a general reserve using a percentage that is established based upon the age of our receivables and our collection history. We establish allowances for balances not yet due and past due accounts based on past experience.

Property, Plant and Equipment

Property, plant and equipment is recorded at historical cost. We provide for depreciation and amortization by charges to operations using the straight-line method in amounts estimated to recover the cost of the building and improvements, equipment, and furniture and fixtures over their estimated useful lives as follows:



Asset Classification		Estimated Useful Lives
Building		30 Years
Building improvements		5-20 Years
Plant equipment and machinery		3-15 Years
Office equipment and information technology		3-10 Years
Haemonetics equipment		3-7 Years

We evaluate the depreciation periods of property, plant and equipment to determine whether events or circumstances warrant revised estimates of useful lives. All property, plant and equipment are also tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable.

Our installed base of devices includes devices owned by us and devices sold to the customer. The asset on our balance sheet classified as Haemonetics equipment consists of medical devices installed at customer sites but owned by Haemonetics. Generally the customer has the right to use it for a period of time as long as they meet the conditions we have established, which among other things, generally include one or more of the following:


•	Purchase and consumption of a certain level of disposable products


•	Payment of monthly rental fees


•	An asset utilization performance metric, such as performing a minimum level of procedures per month per device

Consistent with the impairment tests noted below for other intangible assets subject to amortization, we review Haemonetics equipment and their related useful lives at least once a year, or more frequently if certain conditions arise, to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be recoverable. To conduct these reviews we estimate the future amount and timing of demand for disposables used with these devices, from which we generate revenues. Changes in expected demand can result in additional depreciation expense, which is classified as cost of goods sold. Any significant unanticipated changes in demand could impact the value of our devices and our reported operating results.

Leasehold improvements are depreciated over the lesser of their useful lives or the term of the lease. Maintenance and repairs are generally expensed to operations as incurred. When the repair or maintenance costs significantly extend the life of the asset, these costs may be capitalized. When equipment and improvements are sold or otherwise disposed of, the asset cost and accumulated depreciation are removed from the accounts, and the resulting gain or loss, if any, is included in the statements of income.

Goodwill and Intangible Assets

Intangible assets acquired in a business combination are recorded under the purchase method of accounting at their estimated fair values at the date of acquisition. Costs associated with the application and award of patents in the U.S. and various other countries are capitalized and amortized on a straight-line basis over their estimated useful life. Goodwill represents the excess purchase price over the fair value of the net tangible and other identifiable intangible assets acquired. We amortize our other intangible assets over their estimated useful lives.

Goodwill is not amortized. Instead goodwill is reviewed for impairment at least annually in accordance with ASC Topic 350, Intangibles - Goodwill and Other, or on an interim basis between annual tests when events or circumstances indicate that it is more likely than not that the fair value of a reporting unit is less than its carrying value. We perform our annual impairment test on the first day of the fiscal fourth quarter for each of our reporting units. We first perform a qualitative test and if necessary, perform a quantitative test.

Prior to fiscal 2014, we determined we operated a single operating segment, blood management solutions, based on our chief operating decision maker ("CODM") primarily using consolidated results to make operating and strategic decisions. Our reporting units for purposes of assessing goodwill impairment prior to fiscal 2014 were medical devices and software. During fiscal 2014, our CODM utilized financial results by operating units organized primarily on geography to make operating and strategic decisions due to changes in the composition in the executive staff reporting to the CODM. Based on these changes we determined the five operating units represent operating segments as defined under ASC 280 - Segment Reporting. Following this change, we determined our reporting units for purposes of assessing goodwill impairment by identifying our operating segments and assessing whether segment management regularly reviews the operating results of any components. Through this process, we concluded that our reporting units were the same as our operating segments, which are the following operating units organized based primarily on geography: North America Plasma, North America Blood Center and Hospital, Europe, Asia-Pacific and Japan. During fiscal 2014, goodwill was reallocated from the medical device and software reporting units to the new reporting units based on a relative fair value basis. For fiscal 2015, there were no changes to operating segments or reporting units for purposes of assessing goodwill impairment.

ASC 350, Intangibles - Goodwill and Other defines the fair value of a reporting unit as the price that would be received to sell the unit as a whole in an orderly transaction between market participants at the measurement date. The quantitative test is based on a discounted cash flow analysis or other valuation techniques, such as the market approach, for each reporting unit. The fair values of our reporting units in fiscal 2013 were determined using the income approach. Under the income approach, the fair value of a reporting unit is based on the present value of future cash flows using appropriate discount rates, growth rates, operating margins and future market conditions amongst others. We changed our valuation approach to assessing goodwill impairment in fiscal 2014 in connection with the change in reporting units. In fiscal 2015 and 2014, we determined the fair value of our reporting units based on the market approach. We utilized the market approach as we determined relevant comparable information was available, and accordingly such method was an appropriate alternative to the income method. Under the market approach, we estimate the fair value of our reporting units based on a combination of, a) market multiples of projected earnings before interest, taxes, depreciation and amortization (“EBITDA”) and b) market multiples of projected net revenues for each individual reporting unit. For the market approach, we use judgment in identifying the relevant comparable-company market multiples, such as recent divestitures/acquisitions, facts and circumstances surrounding the market and growth rates. Management assesses the relevance and reliability of the multiples by considering factors unique to its reporting units, including recent operating results, business plans, economic projections, anticipated future cash flows, and other data. EBITDA and revenue multiples can also be significantly impacted by future growth opportunities for the reporting unit as well as for the company itself, general market and geographic sentiment, and pending or recently completed merger transactions.

These tests showed no evidence of impairment to our goodwill for fiscal 2015, 2014 or 2013 and demonstrated that the fair value of each reporting unit exceeded the reporting unit’s carrying value in each period. During March 2014, circumstances arose that indicated a potential impairment. We performed an interim impairment test and noted that the fair value of our reporting units still exceeded their carrying values.

We review intangible assets subject to amortization at least annually or more frequently if certain conditions arise to determine if any adverse conditions exist that would indicate that the carrying value of an asset or asset group may not be recoverable, or that a change in the remaining useful life is required. Conditions indicating that an impairment exists include but are not limited to a change in the competitive landscape, internal decisions to pursue new or different technology strategies, a loss of a significant customer or a significant change in the marketplace including prices paid for our products or the size of the market for our products. During March 2014, circumstances arose that indicated a potential impairment of certain intangible assets subject to amortization. We performed the recoverability test described below for the relevant asset group and determined expected undiscounted cash flows exceeded the carrying value of the asset group.

If an impairment indicator exists, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset (asset group) exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset (asset group), we will write the carrying value down to the fair value in the period identified.

We generally calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset using a risk-adjusted discount rate. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset (asset group).

If we determine the estimate of an intangible asset's remaining useful life should be reduced based on our expected use of the asset, the remaining carrying amount of the asset is amortized prospectively over the revised estimated useful life.

Accounting for the Costs of Computer Software to be Sold, Leased, or Otherwise Marketed

ASC Topic 985-20, Software, specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers, at which point capitalized costs are amortized over their estimated useful life of five to 10 years. Technological feasibility is established when we have a detailed design of the software and when research and development activities on the underlying device, if applicable, are completed.

We review the net realizable value of capitalized assets periodically to assess the recoverability of amounts capitalized. In the future, the net realizable value may be adversely affected by the loss of a significant customer or a significant change in the market place, which could result in an impairment being recorded.

Other Liabilities

Other liabilities represent items payable or expected to settle within the next twelve months. The items included in the fiscal year end balances were:



(In thousands)	March 28, 2015		March 29, 2014
VAT liabilities	$	4,205	$	7,114
Forward contracts	2,657		1,255
Deferred revenue	22,362		24,777
All other	34,987		26,564
Total	$	64,211	$	59,710

Research and Development Expenses

All research and development costs are expensed as incurred.

Advertising Costs

All advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the consolidated statements of income. Advertising expenses were $4.5 million, $3.6 million, and $4.6 million for 2015, 2014 and 2013, respectively.

Accounting for Shipping and Handling Costs

Shipping and handling costs are included in selling, general and administrative expenses. Freight is classified in cost of goods sold when the customer is charged for freight and in selling, general and administration when the customer is not explicitly charged for freight.

Income Taxes

The income tax provision is calculated for all jurisdictions in which we operate. The income tax provision process involves calculating current taxes due and assessing temporary differences arising from items which are taxable or deductible in different periods for tax and accounting purposes and are recorded as deferred tax assets and liabilities. Deferred tax assets are evaluated for realizability and a valuation allowance is maintained for the portion of our deferred tax assets that are not more-likely-than-not realizable.

We file income tax returns in all jurisdictions in which we operate. We record a liability for uncertain tax positions taken or expected to be taken in income tax returns. Our financial statements reflect expected future tax consequences of such positions presuming the taxing authorities' full knowledge of the position and all relevant facts. We record a liability for the portion of unrecognized tax benefits claimed which we have determined are not more-likely-than-not realizable. These tax reserves have been established based on management's assessment as to the potential exposure attributable to our uncertain tax positions as well as interest and penalties attributable to these uncertain tax positions. All tax reserves are analyzed quarterly and adjustments are made. Tax reserves are reversed when the statute of limitations expires or the matter is considered effectively settled.

Derivative Instruments

We account for our derivative financial instruments in accordance with ASC Topic 815, Derivatives and Hedging (“ASC 815”) and ASC Topic 820, Fair Value Measurements and Disclosures (“ASC 820”). In accordance with ASC 815, we record all derivatives on the balance sheet at fair value. The accounting for the change in the fair value of derivatives depends on the intended use of the derivative, whether we have elected to designate a derivative as a hedging instrument for accounting purposes, and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. In addition, ASC 815 provides that, for derivative instruments that qualify for hedge accounting, changes in the fair value are either (a) offset against the change in fair value of the hedged assets, liabilities, or firm commitments through earnings or (b) recognized in equity until the hedged item is recognized in earnings, depending on whether the derivative is being used to hedge changes in fair value or cash flows. The ineffective portion of a derivative’s change in fair value is immediately recognized in earnings. We do not use derivative financial instruments for trading or speculation purposes.

The gains or losses on the forward foreign exchange rate contracts designated as hedges are recorded in net revenues, cost of goods sold, operating expenses and other (expense) income, net in our consolidated statements of income, depending on the nature of the underlying hedged transactions, when the underlying hedged transaction affects earnings. The cash flows related to the gains and losses are classified in the consolidated statements of cash flows as part of cash flows from operating activities. For those derivative instruments that are not designated as part of a hedging relationship we record the gains or losses in earnings currently. These gains and losses are intended to offset the gains and losses recorded on net monetary assets or liabilities that are denominated in foreign currencies. We recorded foreign currency losses of $1.1 million, $0.5 million, and $0.8 million in fiscal 2015, 2014 and 2013, respectively.

On a quarterly basis, we assess whether the cash flow hedges are highly effective in offsetting changes in the cash flow of the hedged item. We manage the credit risk of the counterparties by dealing only with institutions that we consider financially sound and consider the risk of non-performance to be remote.

Our derivative instruments do not subject our earnings or cash flows to material risk, as gains and losses on these derivatives are intended to offset losses and gains on the item being hedged. We do not enter into derivative transactions for speculative purposes and we do not have any non-derivative instruments that are designated as hedging instruments pursuant to ASC Topic 815.

Stock-Based Compensation

To calculate the grant-date fair value of our stock options we use the Black-Scholes option-pricing model and for performance share units and market stock units we use Monte Carlo Simulation models.

Valuation of Acquisitions

We allocate the amounts we pay for each acquisition to the assets acquired and liabilities assumed based on their estimated fair values at the dates of acquisition, including acquired identifiable intangible assets. We base the estimated fair value of identifiable intangible assets on detailed valuations that use historical information and market assumptions based upon the assumptions of a market participant. We allocate any excess purchase price over the fair value of the net tangible and intangible assets acquired to goodwill.

In certain acquisitions, we have earn-out arrangements or contingent consideration to provide potential future payments to the seller for achieving certain agreed-upon targets. We record the contingent consideration at its fair value at the acquisition date. Generally, we have entered into arrangements with contingent consideration that require payments in cash. As such, we periodically revalue the contingent consideration obligations associated with certain acquisitions to their current fair value and record the change in the fair value as contingent consideration income or expense within selling, general and administrative expense. These changes are recorded in selling, general and administrative expense. Increases or decreases in the fair value of the contingent consideration obligations can result from changes in assumed discount periods and rates, changes in the assumed timing and amount of revenue and expense estimates, and changes in assumed probability with respect to regulatory approval. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, future business and economic conditions, as well as changes in any of the assumptions described above, can materially impact the amount of contingent consideration income or expense we record in any given period.

Concentration of Credit Risk and Significant Customers

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents and accounts receivable. In fiscal 2015 and 2014, no one customer accounted for more than 10% of our revenues. Sales to one unaffiliated Japanese customer, the Japanese Red Cross Society, amounted to $90.1 million for fiscal 2013.

Certain other markets and industries can expose us to concentrations of credit risk. For example, in our plasma business, our sales are concentrated with several large customers. As a result, our accounts receivable extended to any one of these bio-pharmaceutical customers can be significant at any point in time. Also, a portion of our trade accounts receivable outside the United States include sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays. Payment is dependent upon the financial stability and creditworthiness of those countries’ national economies. We have not incurred significant losses on government receivables. We continually evaluate all government receivables for potential collection risks associated with the availability of government funding and reimbursement practices. If the financial condition of customers or the countries’ healthcare systems deteriorate such that their ability to make payments is uncertain, allowances may be required in future periods.

Recent Accounting Pronouncements

Standards to be Implemented

In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. ASU No. 2014-08 limits the requirement to report discontinued operations to disposals of components of an entity that represent strategic shifts that have (or will have) a major effect on an entity’s operations and financial results. The amendments also require expanded disclosures concerning discontinued operations and disclosures of certain financial results attributable to a disposal of a significant component of an entity that does not qualify for discontinued operations reporting. The amendments in ASU No. 2014-08 are effective prospectively for reporting periods beginning on or after December 15, 2014, with early adoption permitted. Management does not believe that the adoption of ASU No. 2014-08 will have a material effect on our Financial Statements.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU No. 2014-09 stipulates that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, an entity should apply the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ASU No. 2014-09 will be effective for the Company retrospectively beginning April 2, 2017, with early adoption not permitted. The impact of adopting ASU No. 2014-09 on our Financial Statements is being assessed by management.

In June 2014, the FASB issued ASU No. 2014-12, Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. ASU No. 2014-12 requires that a performance target that affects vesting and could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in ASC 718, Compensation—Stock Compensation, as it relates to such awards. ASU No. 2014-12 is effective in our first quarter of fiscal 2017 with early adoption permitted using either of two methods: (i) prospective to all awards granted or modified after the effective date; or (ii) retrospective to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter, with the cumulative effect of applying ASU No. 2014-12 as an adjustment to the opening retained earnings balance as of the beginning of the earliest annual period presented in the financial statements. Management does not believe that the adoption of ASU No. 2014-12 will have a material effect on our Financial Statements.

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. ASU No. 2014-15 defines management's responsibility to assess an entity's ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. This guidance will be effective for all entities in the first annual period ending after December 15, 2016; however, early adoption is permitted. Management does not believe that the adoption of ASU No. 2014-15 will have a material effect on our Financial Statements.

In January 2015, the FASB issued ASU No. 2015-01, Income Statement-Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items. ASU No. 2015-01 eliminates from GAAP the concept of extraordinary items. An entity will no longer be required to (1) segregate an extraordinary item from the results of ordinary operations; (2) separately present an extraordinary item on its income statement, net of tax, after income from continuing operations; and (3) disclose income taxes and earnings-per-share data applicable to an extraordinary item. ASU No. 2015-01 will be effective for fiscal years beginning after December 15, 2015. An entity may apply the amendments prospectively or retrospectively to all prior periods presented in the financial statements. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. Management does not believe that the adoption of ASU No. 2015-01 will have a material effect on our Financial Statements.

In February 2015, the FASB issued ASU No. 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis. ASU No. 2015-02 amended the process that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. ASU No. 2015-02 is effective for annual periods ending after December 15, 2015, and for annual periods and interim periods thereafter with early adoption permitted. Management does not believe that the adoption of ASU No. 2015-02 will have a material effect on our Financial Statements.

In April 2015, the FASB issued ASU No. 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. ASU No. 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU No. 2015-03 is effective for annual periods beginning after December 15, 2015, and interim periods within those annual periods. Management does not believe that the adoption of ASU No. 2015-03 will have a material effect on our Financial Statements.

In April 2015, the FASB issued ASU No. 2015-04, Compensation—Retirement Benefits (Topic 715): Practical Expedient for the Measurement Date of an Employer’s Defined Benefit Obligation and Plan Assets. ASU No. 2015-04 provides a practical expedient, for an entity with a fiscal year-end that does not coincide with a month-end, that permits the entity to measure defined benefit plan assets and obligations using the month-end that is closest to the entity's fiscal year-end and apply that practical expedient consistently from year to year. ASU No. 2015-04 is effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early application is permitted. The impact of adopting ASU No. 2015-04 on our Financial Statements is being assessed by management.

In April 2015, the FASB issued ASU No. 2015-05, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement. ASU No. 2015-05 will help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement. ASU No. 2015-05 is effective for interim and annual periods beginning after December 15, 2015 with early adoption permitted. The impact of adopting ASU No. 2015-05 on our Financial Statements is being assessed by management.

ACQUISITIONS

12 Months Ended

Mar. 28, 2015

Business Combinations [Abstract]

ACQUISITIONS

Acquisitions were completed in fiscal 2014 and fiscal 2013. We did not complete any acquisitions in fiscal 2015.

Fiscal Year 2014 Acquisition

Hemerus Acquisition

On April 30, 2013, we completed the acquisition of certain assets of Hemerus Medical, LLC ("Hemerus"), a Minnesota based company that develops innovative technologies for the collection of whole blood and processing and storage of blood components. Hemerus has received U.S Food and Drug Administration (FDA) approval for SOLX® whole blood collection system for eight hour storage of whole blood prior to processing. Hemerus previously received Conformité Européenne or CE Mark in the European Union to market SOLX as the world's first 56-day red blood cell storage solution. We paid $24.1 million and will pay an additional $3.0 million upon a further FDA approval of the SOLX solution for 24 hour storage of whole blood prior to processing. We will also pay up to $14.0 million based on future sales of SOLX-based products through fiscal 2025.

We acquired Hemerus to complement the portfolio of whole blood collection, filtration and processing product lines we recently acquired and to bring greater efficiency and productivity to whole blood collection and processing. Hemerus manufactures and sells manual blood collection systems and filters and has operations in North America. Revenue from the sale of SOLX will be reported within the blood center disposables product line.

The assets acquired from Hemerus were recorded at fair value at the date of acquisition.

The final purchase price allocation is as follows:



Asset class	Amounts recognized as of March 29, 2014
Acquired technology	$	22,800
Trade name	1,900
Customer relationship	600
Goodwill	6,425
Total	$	31,725

The fair value of the acquired assets and liabilities are reflected in the Consolidated Balance Sheets. The acquired assets are amortized over the estimate of their useful lives on a straight-line basis. We recorded $2.5 million and $2.3 million in amortization expense relating to the acquired intangible assets for the fiscal years ended March 28, 2015 and March 29, 2014, respectively.

Goodwill represents the excess of the purchase price over the fair value of the net assets. Goodwill of $6.4 million primarily represents future economic benefits expected to arise from the work force and synergies expected to be gained from the integration of SOLX into our whole blood products. Prior to the acquisition, we had not conducted any business with Hemerus.

Contingent consideration

As described above, we will pay the sellers of the Hemerus assets up to $14.0 million based on future sales of SOLX. We recognized a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We revalue this liability each reporting period and record necessary changes in the fair value in our consolidated statements of income. As of March 28, 2015, the maximum amount of future contingent consideration (undiscounted) that we could be required to pay related to future SOLX sales is $14.0 million. Additionally, we will pay $3.0 million upon FDA approval of the SOLX solution for 24 hour storage of whole blood prior to processing. The carrying value of this liability is $4.7 million as of March 28, 2015.

Contingent consideration liabilities are measured at fair value using projected revenues, discount rates, probabilities of payment and projected payment dates. This Level 3 fair value measurement was performed using a probability-weighted discounted cash flow analysis over a ten year period.

Increases or decreases in the fair value of our contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing and amount of revenue estimates or likelihood of earning revenue. Projected revenues are based on our most recent internal forecast and analysis.

Fiscal Year 2013 Acquisition

Whole Blood Acquisition

On August 1, 2012, we completed the acquisition from Pall Corporation (“Pall”) of substantially all of the assets relating to its blood collection, filtration, processing, storage, and re-infusion product lines, and all of the outstanding equity interest in Pall Mexico Manufacturing, S. de R.L. de C.V., a subsidiary of Pall based in Mexico pursuant to an Asset Purchase Agreement (the “Purchase Agreement”) with Pall. We refer to the acquired business as the “whole blood business.”

At the closing of the transaction, we paid a total consideration of $535.2 million in cash and $0.5 million in shares following resolution of post-closing adjustments for working capital and historical earnings levels. We anticipate paying an additional $15.0 million upon replication and delivery of certain manufacturing assets of Pall's filter media business to Haemonetics by 2018. Until that time, Pall will manufacture and sell filter media to Haemonetics under a supply agreement.

We entered into a credit agreement on August 1, 2012 in connection with the transaction which includes a $475.0 million term loan to fund the majority of the cash paid to Pall. See Note 8 for a detailed description of the key terms and provisions of the credit agreement.

We acquired the whole blood business to provide access to the manual collection and whole blood markets and provide scope for introduction of automated solutions in those markets. The whole blood business manufactures and sells manual blood collection systems and filters and has operations in North America, Europe and Asia Pacific countries. Revenue from the sale of whole blood disposables has been reported within the blood center disposables product line since the date of acquisition.

The assets and liabilities acquired from Pall were recorded at fair value at the date of acquisition. We completed the allocation of the purchase price to the estimated fair value of the acquired assets and liabilities in June 2013 and is summarized below:



Asset class	Amounts Recognized as of March 30, 2013
(In thousands)
Inventories	$	49,917
Property, plant and equipment	85,984
Intangible assets	188,500
Other assets/liabilities, net	(6,166		)
Goodwill	216,940
Fair value of net assets acquired	$	535,175

The fair value of the acquired assets and liabilities are reflected in the Consolidated Balance Sheets. The $188.5 million of acquired intangible assets was allocated to acquired technology and customer relationships at fair values of $61.0 million and $127.5 million, respectively. The acquired intangible assets were initially amortized over their estimated useful lives of 12 years on a straight-line basis. We adopted the straight-line amortization of 12 years as it best reflected the pattern of benefits. As of March 29, 2014, the remaining estimated useful life of the customer relationship assets was adjusted to 8 years to better reflect its current pattern of benefits. We recorded $18.8 million, $15.7 million and $10.5 million in amortization expense relating to the acquired intangible assets for the fiscal years ended March 28, 2015, March 29, 2014 and March 30, 2013, respectively.

Goodwill represents the excess of the purchase price over the fair value of the net assets. Goodwill of $216.9 million represents future economic benefits expected to arise from work force at the various plants and locations and significant technological know-how in filter manufacturing. All of the goodwill is deductible for tax purposes.

Revenue for the acquired whole blood business included in our operating results was $143.9 million in fiscal 2015, $190.7 million in fiscal 2014 and $138.4 million in fiscal 2013.

The following represents the pro forma consolidated statements of income for the fiscal year ended March 30, 2013, as if the acquisition had been included in our consolidated results as beginning April 1, 2012:



(In thousands, except per share amounts)	March 30, 2013
Net Sales	$	963,923
Net Income	$	56,540
Basic EPS	$	1.10
Diluted EPS	$	1.08

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

PRODUCT WARRANTIES

12 Months Ended

Mar. 28, 2015

Product Warranties Disclosures [Abstract]

PRODUCT WARRANTIES

We generally provide a warranty on parts and labor for one year after the sale and installation of each device. We also warrant our disposables products through their use or expiration. We estimate our potential warranty expense based on our historical warranty experience, and we periodically assess the adequacy of our warranty accrual and make adjustments as necessary.



(In thousands)	March 28, 2015			March 29, 2014
Warranty accrual as of the beginning of the year	$	590		$	673
Warranty provision	1,199			1,340
Warranty spending	(1,258		)	(1,423		)
Warranty accrual as of the end of the year	$	531		$	590

INVENTORIES

12 Months Ended

Mar. 28, 2015

Inventory Disclosure [Abstract]

INVENTORIES

Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method.



(In thousands)	March 28, 2015		March 29, 2014
Raw materials	$	71,794	$	72,508
Work-in-process	12,462		7,383
Finished goods	126,821		117,770
Total Inventory	$	211,077	$	197,661

GOODWILL AND INTANGIBLE ASSETS

12 Months Ended

Mar. 28, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS

Goodwill

The changes in the carrying amount of goodwill for fiscal 2015 and 2014 are as follows:



(In thousands)
Carrying amount as of March 30, 2013	$	330,474
Hemerus acquisition	6,425
Effects of change in foreign currency exchange rates	(131		)
Carrying amount as of March 29, 2014	$	336,768
Effects of change in foreign currency exchange rates	(2,458		)
Carrying amount as of March 28, 2015	$	334,310

Intangible Assets

Intangible assets include the value assigned to license rights and other developed technology, patents, customer contracts and relationships and trade names. The estimated useful lives for all of these intangible assets are 2 to 19 years. The gross carrying amount of intangible assets and the related accumulated amortization as of March 28, 2015 and March 29, 2014 is as follows:



(In thousands)	Gross Carrying Amount		Accumulated Amortization		Net		Weighted Average Useful Life
							(In years)
As of March 28, 2015
Patents	$	10,473	$	7,373	$	3,100	9
Capitalized software	39,690		5,654		34,036		7
Other developed technology	124,573		46,474		78,099		12
Customer contracts and related relationships	195,985		70,440		125,545		10
Trade names	7,042		3,234		3,808		11
Total intangibles	$	377,763	$	133,175	$	244,588	10



(In thousands)	Gross Carrying Amount		Accumulated Amortization		Net		Weighted Average Useful Life
							(In years)
As of March 29, 2014
Patents	$	9,543	$	7,039	$	2,504	9
Capitalized software	31,750		2,414		29,336		4
Other developed technology	123,525		36,632		86,893		12
Customer contracts and related relationships	200,694		52,741		147,953		12
Trade names	7,341		2,868		4,473		11
Total intangibles	$	372,853	$	101,694	$	271,159	11

The changes to the net carrying value of our intangible assets from March 29, 2014 to March 28, 2015 reflect investment in capitalized software and other less significant intangible assets, amortization expense and the effect of exchange rate changes in the translation of our intangible assets held by our international subsidiaries.

Aggregate amortization expense for amortized intangible assets for fiscal year 2015, 2014, and 2013 was $33.5 million, $29.2 million, and $22.1 million, respectively. Future annual amortization expense on intangible assets is estimated to be as follows:



Fiscal Year	Amount (in thousands)
2016	$	33,752
2017	$	32,998
2018	$	32,165
2019	$	30,470
2020 and thereafter	$	104,544

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

DERIVATIVES AND FAIR VALUE MEASUREMENTS

12 Months Ended

Mar. 28, 2015

Derivatives and Fair Value Measurements [Abstract]

DERIVATIVES AND FAIR VALUE MEASUREMENTS

We manufacture, market and sell our products globally. For the fiscal year ended March 28, 2015, approximately 45.6% of our sales were generated outside the U.S. in local currencies. We also incur certain manufacturing, marketing and selling costs in international markets in local currency.

Accordingly, our earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the U.S. Dollar, our reporting currency. We have a program in place that is designed to mitigate our exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize for a period of time, the unforeseen impact on our financial results from changes in foreign exchange rates. We utilize foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily the Japanese Yen and the Euro, and to a lesser extent the Swiss Franc, Australian Dollar, British Pound Sterling, Canadian Dollar and the Mexican Peso. This does not eliminate the volatility of foreign exchange rates, but because we generally enter into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation.

Designated Foreign Currency Hedge Contracts

All of our designated foreign currency hedge contracts as of March 28, 2015 and March 29, 2014 were cash flow hedges under ASC Topic 815, Derivatives and Hedging. We record the effective portion of any change in the fair value of designated foreign currency hedge contracts in Other Comprehensive Income in the Statement of Stockholders’ Equity until the related third-party transaction occurs. Once the related third-party transaction occurs, we reclassify the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, we would reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. We had designated foreign currency hedge contracts outstanding in the contract amount of $145.8 million as of March 28, 2015 and $157.9 million as of March 29, 2014.

During fiscal 2015, we recognized net gains of $6.5 million in earnings on our cash flow hedges, compared to recognized net gains of $8.6 million and $2.7 million during fiscal 2014 and 2013, respectively. For the fiscal year ended March 28, 2015, $12.2 million of gains, net of tax, were recorded in Accumulated Other Comprehensive Income to recognize the effective portion of the fair value of any designated foreign currency hedge contracts that are, or previously were, designated as foreign currency cash flow hedges, as compared to net gains of $3.7 million, net of tax, for the fiscal year ended March 29, 2014 and net gains of $5.1 million, net of tax, for the fiscal year ended March 30, 2013. At March 28, 2015, gains of $12.2 million, net of tax, will be reclassified to earnings within the next twelve months. All currency cash flow hedges outstanding as of March 28, 2015 mature within twelve months.

Non-designated Foreign Currency Contracts

We manage our exposure to changes in foreign currency on a consolidated basis to take advantage of offsetting transactions and balances. We use foreign currency forward contracts as a part of our strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month. They are not designated as cash flow or fair value hedges under ASC Topic 815. These forward contracts are marked-to-market with changes in fair value recorded to earnings. We had non-designated foreign currency hedge contracts under ASC Topic 815 outstanding in the contract amount of $45.8 million as of March 28, 2015 and $72.9 million as of March 29, 2014.

Interest Rate Swaps

On August 1, 2012, we entered into a Credit Agreement which provided for a $475.0 million term loan (“Term Loan”). Under the terms of this Credit Agreement, the Company may borrow at a spread to an index, including the LIBOR index of 1-month, 3-months, 6-months, etc. From the date of the Credit Agreement, the Company has chosen to borrow against the 1-month USD-LIBOR-BBA rounded up, if necessary, to the nearest 1/16^th of 1% (“Adjusted LIBOR”). The terms of the Credit Agreement also allow us to borrow in multiple tranches. As of March 28, 2015, we have four tranches outstanding.

Accordingly, our earnings and cash flows are exposed to interest rate risk from changes in Adjusted LIBOR. Part of our interest rate risk management strategy includes the use of interest rate swaps to mitigate our exposure to changes in variable interest rates. Our objective in using interest rate swaps is to add stability to interest expense and to manage and reduce the risk inherent in interest rate fluctuations.

On December 21, 2012, we entered into two interest rate swap agreements ("the swaps"), whereby we receive Adjusted LIBOR and pay an average fixed rate of 0.68% on a total notional value of $250.0 million of debt. The interest rate swaps mature on August 1, 2017. The Company designated the interest rate swaps as a cash flow hedge of variable interest rate risk associated with $250.0 million of indebtedness. For the fiscal years ended March 28, 2015, March 29, 2014 and March 30, 2013, $0.9 million of losses, $1.3 million of gains and $0.8 million of losses, net of tax, were recorded in Accumulated Other Comprehensive Income to recognize the effective portion of the fair value of interest rate swaps that qualify as cash flow hedges, respectively.

Fair Value of Derivative Instruments

The following table presents the effect of our derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC Topic 815 in our consolidated statements of income for the fiscal year ended March 28, 2015.



Derivative Instruments	Amount of Gain/(Loss) Recognized in OCI (Effective Portion)			Amount of Gain/(Loss) Reclassified from OCI into Earnings (Effective Portion)		Location in Statement of Operations	Amount of Gain/(Loss) Excluded from Effectiveness Testing (*)			Location in Statement of Operations
(In thousands)
Designated foreign currency hedge contracts, net of tax	$	12,249		$	6,464	Net revenues, COGS, and SG&A	$	(170	)	Other income (expense), net
Non-designated foreign currency hedge contracts	—			—			$	7,510		Other income (expense)
Designated interest rate swaps, net of tax	$	(878	)	$	—	Interest income (expense), net	$	—



(*)		We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.

We did not have fair value hedges or net investment hedges outstanding as of March 28, 2015 or March 29, 2014. As of March 28, 2015, the amount recognized as a deferred tax liability for designated foreign currency hedges was $0.8 million and the amount recognized as a deferred tax asset for interest rate swap hedges was $0.1 million.

ASC Topic 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by ASC Topic 820, Fair Value Measurements and Disclosures, by considering the estimated amount we would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets, and our creditworthiness for liabilities. In certain instances, we may utilize financial models to measure fair value. Generally, we use inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of March 28, 2015, we have classified our derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC Topic 815, as discussed below, because these observable inputs are available for substantially the full term of our derivative instruments.

The following tables present the fair value of our derivative instruments as they appear in our consolidated balance sheets as of March 28, 2015 and March 29, 2014 by type of contract and whether it is a qualifying hedge under ASC Topic 815.



(In thousands)	Location in Balance Sheet	Balance as of March 28, 2015		Balance as of March 29, 2014
Derivative Assets:
Designated foreign currency hedge contracts	Other current assets	$	9,740	$	2,574
Designated interest rate swaps	Other current assets	—		1,250
		$	9,740	$	3,824
Derivative Liabilities:
Designated foreign currency hedge contracts	Other current liabilities	$	2,499	$	1,255
Designated interest rate swaps	Other current liabilities	159		—
		$	2,658	$	1,255

Other Fair Value Measurements

ASC Topic 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and expands disclosures about fair value measurements. ASC Topic 820 does not require any new fair value measurements; rather, it applies to other accounting pronouncements that require or permit fair value measurements. In accordance with ASC Topic 820, for the fiscal years ended March 28, 2015 and March 29, 2014, we applied the requirements under ASC Topic 820 to our non-financial assets and non-financial liabilities. As we did not have an impairment of any non-financial assets or non-financial liabilities, there was no disclosure required relating to our non-financial assets or non-financial liabilities.

On a recurring basis, we measure certain financial assets and financial liabilities at fair value, including our money market funds, foreign currency hedge contracts, and contingent consideration. ASC Topic 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. We base fair value upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value.

ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:


•	Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.


•	Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.


•	Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

Our money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

Fair Value Measured on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of March 28, 2015 and March 29, 2014:



As of March 28, 2015	Quoted Market Prices for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
	(In thousands)		(In thousands)		(In thousands)		(In thousands)
Assets
Money market funds	$	119,946	$	—	$	—	$	119,946
Foreign currency hedge contracts	—		9,740		—		9,740
	$	119,946	$	9,740	$	—	$	129,686
Liabilities
Foreign currency hedge contracts	$	—	$	2,499	$	—	$	2,499
Interest rate swap	—		159		—		159
Contingent consideration	—		—		4,727		4,727
	$	—	$	2,658	$	4,727	$	7,385



As of March 29, 2014	Quoted Market Prices for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
	(In thousands)		(In thousands)		(In thousands)		(In thousands)
Assets
Money market funds	$	135,378	$	—	$	—	$	135,378
Forward currency hedge contracts	—		2,574		—		2,574
Interest rate swap	—		1,250		—		1,250
	$	135,378	$	3,824	$	—	$	139,202
Liabilities
Forward currency hedge contracts	$	—	$	1,255	$	—	$	1,255
Contingent consideration	—		—		7,645		7,645
	$	—	$	1,255	$	7,645	$	8,900

For the fiscal years ended March 28, 2015 and March 29, 2014, non-designated foreign currency hedge contracts were not significant and are not disclosed separately in the above tables.

Contingent consideration

Hemerus

A description of the methods used to determine the fair value of the Level 3 liabilities is included within Note 3, Acquisitions. The table below provides a reconciliation of the beginning and ending Level 3 liabilities for the year ended March 28, 2015.



(In thousands)	Fair value measurements using significant unobservable inputs (Level 3)
Contingent consideration as of March 29, 2014	$	7,645
Fair value adjustment	(2,918		)
Ending balance	$	4,727

The fair value adjustment to contingent consideration was a result of updated assumptions pertaining to timing and unit volumes.

Other Fair Value Disclosures

The Term Loan is carried at amortized cost and accounts receivable and accounts payable are also reported at their cost which approximates fair value.

NOTES PAYABLE AND LONG-TERM DEBT

12 Months Ended

Mar. 28, 2015

Notes Payable and Long-Term Debt [Abstract]

NOTES PAYABLE AND LONG-TERM DEBT

Notes payable and long-term debt consisted of the following:



(In thousands)	March 28, 2015			March 29, 2014
Term loan, net of financing fees	$	426,814		$	435,338
Real estate mortgage	851			1,906
Bank loans and other borrowings	226			443
Less current portion	(21,522		)	(45,630		)
Long-term debt	$	406,369		$	392,057

On August 1, 2012 in connection with the acquisition of the whole blood business, we entered into a credit agreement ("Credit Agreement") with certain lenders (together, “Lenders”) which provided for a $475.0 million term loan and a $50.0 million revolving loan (the “Revolving Credit Facility”), and together with the Term Loan, (the “Credit Facilities”). The Credit Facilities had a term of five years and matured on August 1, 2017.

Under the terms of this Credit Agreement, the Company may borrow at a spread to an index, including the LIBOR index of 1-month, 3-months, 6-months, etc. From the date of the Credit Agreement, the Company has chosen to borrow against the 1-month USD-LIBOR-BBA rounded up, if necessary, to the nearest 1/16^th of 1%. The terms of the Credit Agreement also allow the Company to borrow in multiple tranches. The Company currently borrows in four tranches.

At closing, we borrowed the Term Loan and used the proceeds to pay Pall for the acquisition of the assets described in Note 3. Interest for the Credit Facilities was based on Adjusted LIBOR plus a range of 1.125% to 1.500% depending on the achievement of leverage ratios and customary credit terms which included financial and negative covenants. Revolving loans may be borrowed, repaid and re-borrowed to fund our working capital needs and for other general corporate purposes. The current margin of the Term Loan is 1.375% over Adjusted LIBOR and our effective interest rate inclusive of prepaid financing costs and other fees was approximately 2.0% as of March 28, 2015. The Term Loan or portions thereof may be prepaid at any time, or from time to time without penalty. Once repaid, such amount may not be re-borrowed.

On June 30, 2014, we modified our existing Credit Facilities by extending the maturity date to July 1, 2019, extending the principal repayments of the Term Loan, and modifying certain restrictive covenants to allow greater operational flexibility and enhanced near term liquidity. In addition, the amended Credit Agreement provides for a $100.0 million Revolving Credit Facility and establishes interest rates in the range of LIBOR plus 1.125% to 1.500% depending on certain conditions. At March 28, 2015, $379.4 million was outstanding under the Term Loan and $50.0 million was outstanding on the Revolving Credit Facility, both with an interest rate of 1.5625%. No additional amounts were borrowed as a result of this modification. The fair value of debt approximates its current value of approximately $429.4 million as of March 28, 2015.

Under the Credit Facilities, we are required to maintain a Consolidated Total Leverage Ratio not to exceed 3.0:1.0 and a Consolidated Interest Coverage Ratio not to be less than 4.0:1.0 during periods when the Credit Facilities are outstanding. In addition, we are required to satisfy these covenants, on a pro forma basis, in connection with any new borrowings (including any letter of credit issuances) on the Revolving Credit Facility as of the time of such borrowings. The Consolidated Interest Coverage Ratio is calculated as the Consolidated EBITDA divided by Consolidated Interest Expense while the Consolidated Total Leverage Ratio is calculated as Consolidated Total Debt divided by Consolidated EBITDA. Consolidated EBITDA includes EBITDA adjusted by non-recurring and unusual transactions specifically as defined in the Credit Facilities.

The Credit Facilities also contain usual and customary non-financial affirmative and negative covenants which include certain restrictions with respect to subsequent indebtedness, liens, loans and investments (including acquisitions), financial reporting obligations, mergers, consolidations, dissolutions or liquidation, asset sales, affiliate transactions, change of our business, capital expenditures, share repurchase and other restricted payments. These covenants are subject to important exceptions and qualifications set forth in the Credit Agreement.

Any failure to comply with the financial and operating covenants of the Credit Facilities would prevent us from being able to borrow additional funds and would constitute a default, which could result in, among other things, the amounts outstanding including all accrued interest and unpaid fees, becoming immediately due and payable. In addition, the Credit Facilities include customary events of default, in certain cases subject to customary cure periods. As of March 28, 2015, we were in compliance with the covenants.

Commitment fee

Pursuant to the Credit Agreement we are required to pay the Lenders, on the last day of each calendar quarter, a commitment fee on the unused portion of the Revolving Credit Facility. The commitment fee is subject to a pricing grid based on our Consolidated Total Leverage Ratio. The commitment fee ranges from 0.175% to 0.300%. The current commitment fee on the undrawn portion of the Revolving Credit Facility is 0.250%.

Debt issuance costs and interest

Expenses associated with the issuance of the Term Loan were capitalized and are amortized as additional interest expense over the five years using the effective interest method. In connection with the Term Loan, we initially recorded deferred financing costs of $5.5 million and we recorded additional deferred financing costs of $1.0 million in connection with the June 30, 2014 modification, of which $2.6 million remains as a debt discount. The debt discount is netted against the $429.4 million balance, resulting in a net note payable of $426.8 million. The debt discount will also be amortized as additional interest expense over the life of the term loan.

Interest expense was $8.5 million and $8.9 million for the fiscal years ended March 28, 2015 and March 29, 2014, respectively. Accrued interest associated with our outstanding debt is included as a component of accrued expenses and other current liabilities in the accompanying consolidated balance sheets. As of March 28, 2015, accrued interest totaled $0.6 million.

Other Credit Facilities

The other debt as of March 28, 2015 includes the real estate mortgage loan of $0.9 million and short term bank borrowings of $0.2 million under operating lines of credit.

In December 2000, we entered into a $10.0 million real estate mortgage agreement (the “Mortgage Agreement”) with an investment firm. The Mortgage Agreement requires principal and interest payments of $0.1 million per month for a period of 180 months, commencing February 1, 2001. The Mortgage Agreement provides for interest to accrue on the unpaid principal balance at a rate of 8.41% per annum. Borrowings under the Mortgage Agreement, with a carrying value of approximately $0.9 million and $1.9 million as of March 28, 2015 and March 29, 2014, respectively, are secured by the land, building and building improvements at our headquarters and manufacturing facility in the U.S. There are no financial covenants in the terms and conditions of this agreement.

Maturity Profile

The maturity profile of all gross long-term debt, exclusive of debt discounts, as of March 28, 2015 is presented below:



Fiscal year (in thousands)	Mortgage Obligation		Credit Facilities		Bank loans and other borrowings		Total
2016	$	851	$	21,342	$	144	$	22,337
2017	—		42,683		65		42,748
2018	—		45,054		17		45,071
2019	—		151,763		—		151,763
2020	—		168,564		—		168,564
	$	851	$	429,406	$	226	$	430,483

INCOME TAXES

12 Months Ended

Mar. 28, 2015

Income Tax Disclosure [Abstract]

INCOME TAXES

Domestic and foreign income before provision for income tax is as follows:



(In thousands)	March 28, 2015			March 29, 2014			March 30, 2013
Domestic	$	(17,265	)	$	(6,859	)	$	17,360
Foreign	48,430			43,260			32,537
Total	$	31,165		$	36,401		$	49,897

The income tax provision contains the following components:



(In thousands)	March 28, 2015			March 29, 2014			March 30, 2013
Current
Federal	$	3,526		$	(4,896	)	$	3,795
State	898			873			1,324
Foreign	5,614			5,478			5,389
Total current	$	10,038		$	1,455		$	10,508
Deferred
Federal	1,227			(1,785		)	1,644
State	3,215			207			(229		)
Foreign	(212		)	1,376			(826		)
Total deferred	$	4,230		$	(202	)	$	589
Total	$	14,268		$	1,253		$	11,097

Our subsidiary in Puerto Rico has been granted a fifteen year tax grant which expires in 2027. Our qualification for the tax grant is dependent on the continuation of our manufacturing activities in Puerto Rico. We benefit from a reduced tax rate on our earnings in Puerto Rico under the tax grant.

Our subsidiary in Switzerland operates as a principle company for direct federal tax purposes. Operating under this structure affords our Swiss subsidiary a reduced tax rate in Switzerland. Our Swiss subsidiary also operates under a 10 year tax holiday set to expire in 2018.

Tax affected, significant temporary differences comprising the net deferred tax liability are as follows:



(In thousands)	March 28, 2015			March 29, 2014
Depreciation	$	(23,733	)	$	(23,658	)
Amortization	(24,038		)	(18,618		)
Inventory	6,189			7,371
Hedging	84			321
Accruals, reserves and other	15,927			10,368
Net operating loss carry-forward	5,392			1,507
Stock based compensation	10,652			8,757
Tax credit carry-forward, net	8,678			2,660
Gross deferred taxes	$	(849	)	$	(11,292	)
Less valuation allowance	(16,027		)	(3,083		)
Net deferred tax liability	$	(16,876	)	$	(14,375	)

The valuation allowance increased by $12.9 million during 2015, primarily due to recording a valuation allowance against domestic deferred tax assets that we have determined are not more-likely-than-not realizable. In determining the need for a valuation allowance, we have assessed the available means of recovering deferred tax assets, including the ability to carryback net operating losses, the existence of reversing temporary differences, the availability of tax planning strategies and available sources of future taxable income. We have also considered the ability to implement certain strategies that would, if necessary, be implemented to accelerate taxable income and use expiring deferred tax assets. We believe we are able to support the deferred tax assets recognized as of the end of the year based on all of the available evidence. The worldwide net deferred tax liability as of March 28, 2015 includes deferred tax liabilities related to amortizable goodwill, which are indefinite lived and are not considered to be a source of taxable income. As of March 28, 2015, we maintain a valuation allowance against the portion of our U.S. net deferred tax assets that are not more-likely-than-not realizable and a full valuation allowance against the net deferred tax assets of certain foreign subsidiaries.

At March 28, 2015, we have U.S. federal net operating loss carry-forwards of approximately $11.7 million, U.S. state net operating loss carry-forwards of $23.6 million, federal tax credit carry-forwards of $6.4 million and state tax credit carry-forwards of $4.0 million that are available to reduce future taxable income. A portion of the federal net operating losses are subject to an annual limitation due to the ownership change limitations set forth under Internal Revenue Code Sections 382. Certain of the aforementioned amounts have not been recognized because they relate to excess stock based compensation. At March 28, 2015, $1.5 million of the federal net operating loss carry-forwards, $4.0 million of the state net operating loss carry-forwards, none of the federal tax credit carry-forwards and none of the state tax credit carry-forwards relate to excess stock based compensation tax deductions for which the benefit will be recorded to additional paid-in capital when recognized. The federal and state net operating losses begin to expire in 2022 and 2019, respectively. The federal and state tax credits begin to expire in 2023 and 2025, respectively.

As of March 28, 2015, we have foreign net operating losses of approximately $6.6 million that are available to reduce future income. Substantially all of our foreign net operating loss carry-forwards have unlimited carryover periods.

Income taxes have not been provided on the undistributed earnings of foreign subsidiaries of approximately $300.2 million, because such earnings are considered to be indefinitely reinvested in the business. The accumulated earnings in the foreign subsidiaries are primarily utilized to fund working capital requirements as our subsidiaries continue to expand their operations, to service existing debt obligations and to fund future foreign acquisitions. We do not believe it is practicable to estimate the amount of income taxes payable on the earnings that are indefinitely reinvested in foreign operations.

The income tax provision from operations differs from tax provision computed at the 35.0% U.S. federal statutory income tax rate due to the following:



(In thousands)	March 28, 2015					March 29, 2014					March 30, 2013
Tax at federal statutory rate	$	10,907		35.0	%	$	12,739		35.0	%	$	17,464		35.0	%
Domestic manufacturing deduction	—			—	%	—			—	%	(504		)	(1.0	)%
Difference between U.S. and foreign tax	(6,929		)	(22.2	)%	(10,846		)	(29.8	)%	(5,584		)	(11.2	)%
State income taxes net of federal benefit	(818		)	(2.6	)%	(252		)	(0.7	)%	718			1.4	%
Change in uncertain tax positions	(1,762		)	(5.7	)%	(1,678		)	(4.6	)%	(580		)	(1.2	)%
Intercompany loan deduction	—			—	%	(2,185		)	(6.0	)%	—			—	%
Non-deductible expenses	1,237			4.0	%	1,035			2.8	%	1,178			2.4	%
Research credits	(1,000		)	(3.2	)%	(688		)	(1.9	)%	(799		)	(1.6	)%
Naked Credit	3,826			12.3	%	—			—	%	—			—	%
Valuation allowance	8,524			27.4	%	2,400			6.6	%	—			—	%
Other, net	283			0.8	%	728			2.0	%	(796		)	(1.6	)%
Income tax provision	$	14,268		45.8	%	$	1,253		3.4	%	$	11,097		22.2	%

Unrecognized Tax Benefits

Unrecognized tax benefits represent uncertain tax positions for which reserves have been established. As of March 28, 2015, we had $7.1 million of unrecognized tax benefits, of which $2.0 million would impact the effective tax rate, if recognized. As of March 29, 2014, we had $5.6 million of unrecognized tax benefits, all of which would impact the effective tax rate, if recognized. At March 30, 2013, we had $6.9 million of unrecognized tax benefits, of which $6.7 million would impact the effective tax rate, if recognized.

During the fiscal year ended March 28, 2015 our unrecognized tax benefits were increased by $1.5 million due primarily to tax reserve increases for prior year additions, partially offset by the release of certain previously established reserves in connection with the closure of tax statutes of limitations.

The following table summarizes the activity related to our gross unrecognized tax benefits for the fiscal years ended March 28, 2015, March 29, 2014 and March 30, 2013:



(In thousands)	March 28, 2015			March 29, 2014			March 30, 2013
Beginning Balance	$	5,604		$	6,930		$	6,885
Additions based upon positions related to the current year	—			—			1,192
Additions for tax positions of prior years	3,234			990			18
Settlements with taxing authorities	(338		)	—			(80		)
Closure of statute of limitations	(1,430		)	(2,316		)	(1,085		)
Ending Balance	$	7,070		$	5,604		$	6,930

As of March 28, 2015 we anticipate that the liability for unrecognized tax benefits for uncertain tax positions could change by up to $0.9 million in the next twelve months, as a result of closure of various statutes of limitations.

Our historic practice has been and continues to be to recognize interest and penalties related to Federal, state and foreign income tax matters in income tax expense. Approximately $0.7 million and $0.8 million of gross interest and penalties were accrued at March 28, 2015 and March 29, 2014, respectively and is not included in the amounts above. There was a benefit included in tax expense of $0.3 million, zero and $0.1 million for the periods ended March 28, 2015, March 29, 2014 and March 30, 2013, respectively.

We conduct business globally and, as a result, file consolidated and separate Federal, state and foreign income tax returns in multiple jurisdictions. In the normal course of business, we are subject to examination by taxing authorities throughout the world. With a few exceptions overseas, we are no longer subject to U.S. federal, state and local, or foreign income tax examinations for years before 2012.

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Mar. 28, 2015

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

We lease facilities and certain equipment under operating leases expiring at various dates through fiscal 2028. Facility leases require us to pay certain insurance expenses, maintenance costs and real estate taxes.

Approximate future basic rental commitments under operating leases as of March 28, 2015 are as follows (in thousands):



Fiscal Year Ending
(In thousands)
2016	$	6,797
2017	4,780
2018	3,758
2019	2,427
2020 and thereafter	11,585
	$	29,347

Rent expense in fiscal 2015, 2014, and 2013 was $6.3 million, $7.7 million and $7.0 million, respectively. Some of the Company's operating leases include renewal provisions, escalation clauses and options to purchase the facilities that we lease.

We are presently engaged in various legal actions, and although our ultimate liability cannot be determined at the present time, we believe, based on consultation with counsel, that any such liability will not materially affect our consolidated financial position or our results of operations.

Italian Employment Litigation

Our Italian manufacturing subsidiary is party to several actions initiated by employees of the facility in Ascoli-Piceno, Italy where we have ceased manufacturing operations. These include actions claiming (i) working conditions and minimum salaries should have been established by either a different classification under their national collective bargaining agreement or a different agreement altogether, (ii) certain solidarity agreements, which are arrangements between the Company, employees and the government to continue full pay and benefits for employees who would otherwise be terminated in times of low demand, are void, and (iii) payment of the extra time used for changing into and out of the working clothes at the beginning and end of each shift.

In addition, a union represented in the Ascoli plant has filed an action claiming that the Company discriminated against it in favor of three other represented unions by (i) interfering with an employee referendum, (ii) interfering with an employee petition to recall union representatives from office, and (iii) excluding the union from certain meetings.

Finally, we have been added as defendants on claims filed against Pall Corporation prior to our acquisition of the plant in August 2012. These claims relate to agreements to "freeze" benefit allowances for a certain period in exchange for Pall's commitments on hiring and plant investment.

As of March 28, 2015, the total amount of damages claimed by the plaintiffs in these matters is approximately $3.7 million; however, it is not possible at this point in the proceedings to accurately evaluate the likelihood or amount of any potential losses. We may receive other similar claims in the future.

CAPITAL STOCK

12 Months Ended

Mar. 28, 2015

Capital Stock [Abstract]

CAPITAL STOCK

Stock Plans

The 2005 Long-Term Incentive Compensation Plan (the “2005 Incentive Compensation Plan”) permits the award of non-qualified stock options, incentive stock options, stock appreciation rights, restricted stock, deferred stock/restricted stock units, other stock units and performance shares to the Company’s key employees, officers and directors. The 2005 Incentive Compensation Plan is administered by the Compensation Committee of the Board of Directors (the “Committee”) consisting of three independent members of our Board of Directors.

The maximum number of shares available for award under the 2005 Incentive Compensation Plan is 15,024,920. The maximum number of shares that may be issued pursuant to incentive stock options may not exceed 500,000. Any shares that are subject to the award of stock options shall be counted against this limit as one (1) share for every one (1) share issued. Any shares that are subject to awards other than stock options shall be counted against this limit as 3.26 shares for every one (1) share granted.

Each award has different terms under the 2005 Incentive Compensation Plan. Options, Restricted Stock Awards and Restricted Stock Units become exercisable, or in the case of restricted stock, the resale restrictions are released in a manner determined by the Committee, generally over a four year period for employees and one year from grant for non-employee directors, and all options expire not more than 7 years from the date of the grant. The exercise price for options granted under the 2005 Incentive Compensation Plan is determined by the Committee, but in no event shall such exercise price be less than the fair market value of the common stock at the time of the grant. Holders of market stock units are eligible to receive a share of Haemonetics’ stock for each market stock unit based on the performance of the stock through March 31, 2017. If our stock is below a minimum threshold price of $50 per share during the relevant measurement period, the holders receive no market share units. If the stock achieves certain price levels, the holders are eligible to receive up to three times the “target” amount of market share units. As a result, we may issue up to 863,046 shares at a stock price of $85 per share or higher in connection with these grants.

At March 28, 2015, there were outstanding options to purchase 3,761,666 shares, 357,547 shares of restricted stock outstanding and 287,682 market stock units outstanding under this plan and 999,243 shares available for future grant.

The Company had a long-term incentive stock option plan and a non-qualified stock option plan, (the “2000 Long-term Incentive Plan”) which permitted the issuance of a maximum of 7,000,000 shares of our common stock pursuant to incentive and non-qualified stock options granted to key employees, officers and directors. The plan was terminated in connection with the adoption of the 2005 Incentive Compensation Plan. The remaining 55,750 options outstanding under this plan were exercised in fiscal 2015 and no further options will be granted under this plan.

The Company has an Employee Stock Purchase Plan (the “Purchase Plan”) under which a maximum of 1,400,000 shares (subject to adjustment for stock splits and similar changes) of common stock may be purchased by eligible employees. Substantially all of our full-time employees are eligible to participate in the Purchase Plan.

The Purchase Plan provides for two “purchase periods” within each of our fiscal years, the first commencing on November 1 of each year and continuing through April 30 of the next calendar year, and the second commencing on May 1 of each year and continuing through October 31 of such year. Shares are purchased through an accumulation of payroll deductions (of not less than 2% or more than 15% of compensation, as defined) for the number of whole shares determined by dividing the balance in the employee’s account on the last day of the purchase period by the purchase price per share for the stock determined under the Purchase Plan. The purchase price for shares is the lower of 85% of the fair market value of the common stock at the beginning of the purchase period, or 85% of such value at the end of the purchase period.

Stock-based compensation expense of $14.1 million, $13.1 million, and $11.0 million was recognized under ASC Topic 718, Compensation — Stock Compensation, for the fiscal year ended March 28, 2015, March 29, 2014, and March 30, 2013, respectively. The related income tax benefit recognized was $4.5 million, $4.3 million, and $3.5 million for the fiscal year ended March 28, 2015, March 29, 2014, and March 30, 2013, respectively. We recognize stock-based compensation on a straight line basis.

ASC Topic 718 requires that cash flows relating to the benefits of tax deductions in excess of stock compensation cost recognized be reported as a financing cash flow, rather than as an operating cash flow. This excess tax benefit was $1.6 million, $2.4 million, and $4.1 million for the fiscal year ended March 28, 2015, March 29, 2014, and March 30, 2013, respectively.

Stock Options

A summary of stock option activity for the fiscal year ended March 28, 2015 is as follows:



	Options Outstanding (shares)		Weighted Average Exercise Price per Share		Weighted Average Remaining Life (years)	Aggregate Intrinsic Value ($000’s)
Outstanding at March 29, 2014	3,834,372		$	32.93	4.19	$	9,436
Granted	592,024		34.87
Exercised	(500,103	)	26.14
Forfeited	(164,627	)	38.13
Outstanding at March 28, 2015	3,761,666		$	33.90	4.02	$	37,067

Exercisable at March 28, 2015	2,281,022		$	31.57	2.92	$	27,826

Vested or expected to vest at March 28, 2015	3,596,493		$	33.73	3.93	$	36,066

The total intrinsic value of options exercised was $5.6 million, $11.7 million, and $20.9 million during fiscal 2015, 2014, and 2013, respectively.

As of March 28, 2015, there was $9.2 million of total unrecognized compensation cost related to non-vested stock options. This cost is expected to be recognized over a weighted average period of 2.37 years.

The fair value was estimated using the Black-Scholes option-pricing model based on the weighted average of the high and low stock prices at the grant date and the weighted average assumptions specific to the underlying options. Expected volatility assumptions are based on the historical volatility of our common stock. The risk-free interest rate was selected based upon yields of U.S. Treasury issues with a term equal to the expected life of the option being valued. The expected life of the option was estimated with reference to historical exercise patterns, the contractual term of the option and the vesting period.

The assumptions utilized for option grants during the periods presented are as follows:



	March 28, 2015		March 29, 2014		March 30, 2013
Volatility	22.5	%	24.8	%	26.4	%
Expected life (years)	4.9		4.9		4.9
Risk-free interest rate	1.5	%	1.3	%	0.8	%
Dividend yield	0.0	%	0.0	%	0.0	%

The weighted average grant date fair value of options to purchase one share granted during 2015, 2014, and 2013 was approximately $7.91, $10.15, and $9.76, respectively.

We have applied, based on an analysis of our historical forfeitures, an annual forfeiture rate of 8% to all unvested stock options as of March 28, 2015 and March 29, 2014, which represents the portion that we expect will be forfeited each year over the vesting period.

Employee Stock Purchase Plan

The fair values of shares purchased under the Employee Stock Purchase Plan are estimated using the Black-Scholes single option-pricing model with the following weighted average assumptions:



	March 28, 2015		March 29, 2014		March 30, 2013
Volatility	23.7	%	22.9	%	24.9	%
Expected life (months)	6		6		6
Risk-free interest rate	0.1	%	0.1	%	0.2	%
Dividend Yield	0.0	%	0.0	%	0.0	%

The weighted average grant date fair value of the six-month option inherent in the Purchase Plan was approximately $7.09, $8.25, and $8.50 during fiscal 2015, 2014, and 2013, respectively.

Performance Stock Units, Restricted Stock Units and Market Stock Units

On October 22, 2014, the Company issued a new type of equity award under its 2005 Incentive Compensation Plan, Performance Share Units, with a target award level of 129,130 shares for 14 senior executives.

The value of these Performance Share Units is based upon the Company’s total shareholder return for the period from October 1, 2014 to their vesting date of September 30, 2017 relative to the total shareholder return of the companies comprising the Standard & Poor's Health Care Equipment Index (the "Index"). These awards are conditioned upon the employees’ continued employment with the Company through the vesting date. If an employee is no longer employed by the Company at the vesting date as a result of a Qualifying Retirement, then the continued employment requirement shall cease to apply and prorated shares awarded will be determined as of the vesting date.

Total shareholder return is equal to the appreciation of the share price during a performance period, plus any dividends paid on the applicable company’s common stock. Relative total shareholder return compares the company's total shareholder return to the Index.

The actual number of shares awarded under a Performance Share Unit may range from 0% to a maximum of 200% of the target award depending upon the Company’s relative total shareholder return. If the Company’s total shareholder return for the performance period is negative, then any share payout will be capped at 100% of the target award, regardless of the Company's performance relative to the Index.

Grant date fair values for the Performance Share Units were estimated using a Monte Carlo Simulation of the Company's and the Index's stock price correlation over three-year time horizons matching the Performance Share Units performance period with a risk free rate of 0.78%, volatility of 20% and 12 months of dividend history.

The estimated fair value, potential shares to be awarded, recognized compensation expense and future compensation expense to be recognized, including estimated forfeitures, for Performance Share Unit awards are as follows:



			For Year Ended March 28, 2015
Performance Period	Award Fair Value as of October 22, 2014		Recognized Compensation Expense		Unrecognized Compensation Expense		Minimum Shares	Target Shares	Maximum Shares
	(Per share)		(In thousands)		(In thousands)
Oct 1, 2014 - Sept 30, 2017	$	35.09	$	662	$	3,869	—	129,130	258,260

As of March 28, 2015, there were 287,682 market stock units outstanding. We determined the fair value of each market stock unit to be $37.42, utilizing a Monte Carlo simulation model based on an expected term of 3.7 years, a risk free rate of 0.9%, volatility of 20% and no dividends. The grant date fair value of these awards totaled $11.2 million and will be expensed evenly over the 3.7 year period through the cliff-vesting date of March 31, 2017.

As of March 28, 2015, there was $13.2 million of total unrecognized compensation cost related to non-vested restricted stock units and market stock units. This cost is expected to be recognized over a weighted average period of 2.37 years.

A summary of performance stock units, restricted stock units and market stock units activity for the fiscal year ended March 28, 2015 is as follows:



	Shares		Weighted Average Market Value at Grant Date
Unvested at March 29, 2014	599,673		$	37.70
Awarded	351,666		$	35.18
Released	(110,048	)	$	36.65
Forfeited	(66,932	)	$	37.83
Unvested at March 28, 2015	774,359		$	36.70

EARNINGS PER SHARE ("EPS")

12 Months Ended

Mar. 28, 2015

Earnings Per Share [Abstract]

EARNINGS PER SHARE (EPS)

EARNINGS PER SHARE (“EPS”)

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations. Basic EPS is computed by dividing net income by weighted average shares outstanding. Diluted EPS includes the effect of potentially dilutive common shares. The common stock weighted average number of shares has been retroactively adjusted for the stock split.



(In thousands, except per share amounts)	March 28, 2015		March 29, 2014		March 30, 2013
Basic EPS
Net income	$	16,897	$	35,148	$	38,800
Weighted average shares	51,533		51,611		51,349
Basic income per share	$	0.33	$	0.68	$	0.76
Diluted EPS
Net income	$	16,897	$	35,148	$	38,800
Basic weighted average shares	51,533		51,611		51,349
Net effect of common stock equivalents	556		766		910
Diluted weighted average shares	52,089		52,377		52,259
Diluted income per share	$	0.32	$	0.67	$	0.74

Weighted average shares outstanding, assuming dilution, excludes the impact of 1.6 million, 1.1 million and 0.5 million stock options for fiscal years 2015, 2014 and 2013, respectively, because these securities were anti-dilutive during the noted periods.

PROPERTY, PLANT AND EQUIPMENT

12 Months Ended

Mar. 28, 2015

Property, Plant and Equipment [Abstract]

PROPERTY, PLANT AND EQUIPMENT

Property and equipment consisted of the following:



(In thousands)	March 28, 2015			March 29, 2014
Land	$	9,468		$	7,168
Building and building improvements	118,384			83,439
Plant equipment and machinery	220,793			236,539
Office equipment and information technology	118,810			111,925
Haemonetics equipment	264,307			262,784
Total	731,762			701,855
Less: accumulated depreciation and amortization	(409,814		)	(430,418		)
Property, plant and equipment, net	$	321,948		$	271,437

Depreciation expense was $52.6 million, $52.6 million, and $43.4 million for fiscal 2015, 2014, and 2013, respectively.

RETIREMENT PLANS

12 Months Ended

Mar. 28, 2015

Compensation and Retirement Disclosure [Abstract]

RETIREMENT PLANS

Defined Contribution Plans

We have a Savings Plus Plan that is a 401(k) plan that allows our U.S. employees to accumulate savings on a pre-tax basis. In addition, matching contributions are made to the Plan based upon pre-established rates. Our matching contributions amounted to approximately $5.8 million in 2015, $6.2 million in 2014, and $4.9 million in 2013. Upon Board approval, additional discretionary contributions can also be made. No discretionary contributions were made for the Savings Plan in fiscal 2015, 2014, or 2013.

Some of our subsidiaries also have defined contribution plans, to which both the employee and the employer make contributions. The employer contributions to these plans totaled $1.0 million, $0.8 million, and $2.4 million in fiscal 2015, 2014, and 2013, respectively.

Defined Benefit Plans

ASC Topic 715, Compensation — Retirement Benefits, requires an employer to: (a) recognize in its statement of financial position an asset for a plan’s over-funded status or a liability for a plan’s under-funded status; (b) measure a plan’s assets and its obligations that determine its funded status as of the end of the employer’s fiscal year (with limited exceptions); and (c) recognize changes in the funded status of a defined benefit post retirement plan in the year in which the changes occur. Accordingly, the Company is required to report changes in its funded status in comprehensive income on its Statement of Stockholders’ Equity and Comprehensive Income.

Benefits under these plans are generally based on either career average or final average salaries and creditable years of service as defined in the plans. The annual cost for these plans is determined using the projected unit credit actuarial cost method that includes actuarial assumptions and estimates which are subject to change.

Some of the our foreign subsidiaries have defined benefit pension plans covering substantially all full time employees at those subsidiaries. Net periodic benefit costs for the plans in the aggregate include the following components:



(In thousands)	March 28, 2015			March 29, 2014			March 30, 2013
Service cost	$	2,979		$	3,351		$	2,759
Interest cost on benefit obligation	686			623			639
Expected (return)/loss on plan assets	(449		)	(435		)	(413		)
Actuarial loss/(gain)	107			88			196
Amortization of unrecognized prior service cost	(29		)	182			(14		)
Amortization of unrecognized transition obligation	45			47			48
Totals	$	3,339		$	3,856		$	3,215

The activity under those defined benefit plans are as follows:



(In thousands)	March 28, 2015			March 29, 2014
Change in Benefit Obligation:
Benefit Obligation, beginning of year	$	(32,621	)	$	(30,126	)
Service cost	(2,979		)	(3,351		)
Interest cost	(686		)	(623		)
Benefits paid	4,902			4,474
Actuarial (loss)/gain	(6,883		)	55
Employee and plan participants contribution	(2,978		)	(2,963		)
Plan Amendments	114			419
Foreign currency changes	564			(506		)
Benefit obligation, end of year	$	(40,567	)	$	(32,621	)
Change in Plan Assets:
Fair value of plan assets, beginning of year	$	19,981		$	19,577
Company contributions	2,112			2,241
Benefits paid	(4,621		)	(4,641		)
Gain/(Loss) on plan assets	506			100
Employee and plan participants contributions	2,851			3,087
Foreign currency changes	2,336			(383		)
Fair value of Plan Assets, end of year	$	23,165		$	19,981
Funded Status	$	(17,402	)	$	(12,640	)
Unrecognized net actuarial loss/(gain)	11,096			5,899
Unrecognized initial obligation	64			94
Unrecognized prior service cost	(459		)	(422		)
Net amount recognized	$	(6,701	)	$	(7,069	)

One of the benefit plans is funded by benefit payments made by the Company. Accordingly that plan has no assets included in the information presented above. The total liability for this plan was $9.2 million and $7.4 million as of March 28, 2015 and March 29, 2014, respectively.

The accumulated benefit obligation for all plans was $34.9 million and $30.9 million for the fiscal year ended March 28, 2015 and March 29, 2014, respectively.

The projected benefit obligation, accumulated benefit obligation, and fair value of plan assets for the pension plans with an accumulated benefit obligation in excess of plan assets were $40.6 million, $34.9 million and $23.2 million, respectively, as of March 28, 2015 and $32.6 million, $30.9 million and $20.0 million, respectively, as of March 29, 2014. There were no plans where the plan assets were greater than the accumulated benefit obligation as of March 28, 2015 and March 29, 2014.

The components of the change recorded in our accumulated other comprehensive income related to our defined benefit plans, net of tax, are as follows (in thousands):



Balance, March 31, 2012	$	(4,253	)
Obligation at transition	556
Actuarial loss	(1,237		)
Prior service cost	(139		)
Balance as of March 30, 2013	$	(5,073	)
Obligation at transition	172
Actuarial loss	(129		)
Prior service cost	438
Balance as of March 29, 2014	$	(4,592	)
Obligation at transition	(19		)
Actuarial loss	(6,198		)
Prior service cost	1,886
Balance as of March 28, 2015	$	(8,923	)

We expect to amortize $0.6 million from accumulated other comprehensive loss during 2016.

The weighted average rates used to determine the net periodic benefit costs and projected benefit obligations were as follows:



	March 28, 2015		March 29, 2014		March 30, 2013
Discount rate	0.93	%	2.02	%	1.97	%
Rate of increased salary levels	1.65	%	1.57	%	1.42	%
Expected long-term rate of return on assets	1.68	%	1.94	%	1.92	%

Assumptions for expected long-term rate of return on plan assets are based upon actual historical returns, future expectations of returns for each asset class and the effect of periodic target asset allocation rebalancing. The results are adjusted for the payment of reasonable expenses of the plan from plan assets.

We have no other material obligation for post-retirement or post-employment benefits.

Our investment policy for pension plans is to balance risk and return through a diversified portfolio to reduce interest rate and market risk. Maturities are managed so that sufficient liquidity exists to meet immediate and future benefit payment requirements.

ASC Topic 820, Fair Value Measurements and Disclosures, provides guidance for reporting and measuring the plan assets of our defined benefit pension plan at fair value as of March 28, 2015. Using the same three-level valuation hierarchy for disclosure of fair value measurements as described in Note 7, all of the assets of the Company’s plan are classified within Level 2 of the fair value hierarchy because the plan assets are primarily insurance contracts.

Expected benefit payments for both plans are estimated using the same assumptions used in determining the company’s benefit obligation at March 28, 2015. Benefit payments will depend on future employment and compensation levels, average years employed and average life spans, among other factors, and changes in any of these factors could significantly affect these estimated future benefit payments.

Estimated future benefit payments during the next five years and in the aggregate for the five fiscal years thereafter, are as follows (in thousands):



Expected Benefit Payments
Fiscal Year 2016	$	1,735
Fiscal Year 2017	$	1,654
Fiscal Year 2018	$	1,502
Fiscal Year 2019	$	1,610
Fiscal Year 2020	$	1,732
Fiscal Year 2021-2024	$	7,493

The Company's contributions for fiscal 2016 are expected to be consistent with the current year.

SEGMENT INFORMATION

12 Months Ended

Mar. 28, 2015

Segment Reporting [Abstract]

SEGMENT INFORMATION

Segment Definition Criteria

We manage a global business which designs, manufactures and markets blood management solutions. Our solutions are marketed through operating segments organized primarily on geography: North America Plasma, North America Blood Center and Hospital, Europe, Asia Pacific and Japan.

ASC 280, Segment Reporting, permits the aggregation of segments which are economically similar as well as similar in all of the following areas: (i) the nature of the products and services, (ii) the nature of the production processes, (iii) the type or class of customer for their products and services, (iv) the methods used to distribute their products or provide their services, and (v) the nature of the regulatory environment.

The Company believes aggregating the operating segments noted above is consistent with the key principles of ASC 280, based on the determination that they are economically similar. The Company believes a single reportable segment is consistent with its basic organizational structure and believes aggregation is consistent with its primary basis for decision making and accordingly does not conflict with the basic principles of ASC 280.

Enterprise Wide Disclosures About Product and Services

We have four global product families: plasma, blood center, hospital, and software solutions.

Our products include whole blood disposables, equipment devices and the related disposables used with these devices. Disposables include part of plasma, blood center, and hospital product families. Plasma consists of the disposables used to perform apheresis for the separation of whole blood components and subsequent collection of plasma to be used as a raw material for biologically derived pharmaceuticals. Blood center consists of disposables which separate whole blood for the subsequent collection of platelets, plasma, red cells, or a combination of these components for transfusion to patients as well as disposables for manual whole blood collection. Hospital consists of surgical disposables (principally the Cell Saver^® autologous blood recovery system targeted to procedures that involve rapid, high volume blood loss such as cardiovascular surgeries), the OrthoPAT^® orthopedic perioperative autotransfusion system designed to operate both during and after surgery to recover and wash the patient’s red cells to prepare them for reinfusion, and diagnostics products (principally the TEG^® Thrombelastograph^® hemostasis analyzer used to help assess a surgical patient’s hemostasis during and after surgery).

Software solutions include information technology platforms that assist blood centers, plasma centers, and hospitals to more effectively manage regulatory compliance and operational efficiency.

Revenues from External Customers:



(In thousands)	March 28, 2015		March 29, 2014		March 30, 2013
Disposable revenues
Plasma disposables	$	319,190	$	291,895	$	268,900
Blood center disposables
Platelet	152,588		156,643		169,602
Red cell	42,700		42,378		49,733
Whole blood	143,905		190,698		138,436
	339,193		389,719		357,771
Hospital disposables
Surgical	62,540		66,876		73,508
OrthoPAT	20,316		25,042		30,230
Diagnostics	42,187		33,302		27,356
	125,043		125,220		131,094
Disposables revenue	783,426		806,834		757,765
Software solutions	72,185		70,441		69,952
Equipment & other	54,762		61,234		64,273
Total revenues	$	910,373	$	938,509	$	891,990

Enterprise Wide Disclosures About Product and Services

Year Ended (in thousands)



March 28, 2015	United States		Other North America		Total North America		Japan		Other Asia		Total Europe		Total Consolidated
Net revenues	$	494,788	$	9,617	$	504,405	$	88,298	$	102,095	$	215,575	$	910,373
Total Assets	$	810,159	$	240,610	$	1,050,769	$	41,621	$	79,084	$	313,943	$	1,485,417
Long-Lived Assets	$	532,187	$	212,548	$	744,735	$	9,230	$	46,857	$	114,318	$	915,140



March 29, 2014	United States		Other North America		Total North America		Japan		Other Asia		Total Europe		Total Consolidated
Net revenues	$	500,719	$	9,557	$	510,276	$	108,679	$	94,762	$	224,792	$	938,509
Total Assets	$	810,409	$	225,998	$	1,036,407	$	53,207	$	53,055	$	371,509	$	1,514,178
Long-Lived Assets	$	519,396	$	211,624	$	731,020	$	11,522	$	17,269	$	131,391	$	891,202



March 30, 2013	United States		Other North America		Total North America		Japan		Other Asia		Total Europe		Total Consolidated
Net revenues	$	454,874	$	6,851	$	461,725	$	120,726	$	84,860	$	224,679	$	891,990
Total Assets	$	830,754	$	225,849	$	1,056,603	$	44,189	$	41,037	$	320,088	$	1,461,917
Long-Lived Assets	$	503,606	$	209,439	$	713,045	$	12,977	$	8,076	$	117,717	$	851,815

The Long-Lived Assets reported above include Goodwill, Intangibles and Net Property, Plant and Equipment.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

RESTRUCTURING

12 Months Ended

Mar. 28, 2015

Restructuring and Related Activities [Abstract]

RESTRUCTURING

On an ongoing basis, we review the global economy, the healthcare industry, and the markets in which we compete. From these reviews we identify opportunities to improve efficiencies, enhance commercial capabilities, better align our resources and offer customers better comprehensive solutions. In order to realize these opportunities, from time to time, we undertake restructuring and other initiatives to transform our business.

On May 1, 2013, we committed to a plan to pursue identified Value Creation and Capture initiatives ("VCC"). These opportunities include investment in product line extensions and next generation products, enhancement of commercial capabilities and a transformation of our manufacturing network. The transformation of our manufacturing network will take place over three years and includes changes to the current manufacturing footprint and supply chain structure (the "Network Plan"). To implement the Network Plan, we are (i) discontinuing manufacturing activities at our Braintree, Massachusetts, Ascoli-Piceno, Italy and Bothwell, Scotland facilities, (ii) creating a technology center of excellence for product development in Braintree, Massachusetts, (iii) expanding our current facility in Tijuana, Mexico, (iv) engaging Sanmina Corporation as a contract manufacturer to produce certain medical equipment, and (v) building a new manufacturing facility in Penang, Malaysia closer to our customers in Asia. See liquidity and capital resources discussion of this MD&A for further discussion of the costs of these activities.

We estimate we will incur approximately $45.0 million of restructuring and restructuring related expense and spend approximately $27.0 million to complete these initiatives in fiscal 2016.

For the year ended March 28, 2015, we incurred $36.9 million of restructuring and restructuring related charges and paid approximately $42.3 million with approximately $13.3 million payable within the next twelve months. The substantial majority of restructuring expenses have been included as a component of selling, general and administrative expense in the accompanying consolidated statements of income and comprehensive income.

The following summarizes the restructuring activity for the fiscal year ended March 28, 2015, March 29, 2014, and March 30, 2013, respectively:



(In thousands)	Balance at March 29, 2014		Cost Incurred		Payments			Less Non-Cash Adjustments			Restructuring Accrual Balance at March 28, 2015
Severance and other employee costs	$	22,908	$	19,879	$	(26,394	)	$	—		$	16,393
Other costs	728		15,362		(15,871		)	—			219
Accelerated depreciation	—		1,326		—			(1,326		)	—
Asset write-down	—		296		—			(296		)	—
	$	23,636	$	36,863	$	(42,265	)	$	(1,622	)	$	16,612



(In thousands)	Balance at March 30, 2013		Cost Incurred		Payments			Less Non-Cash Adjustments			Restructuring Accrual Balance at March 29, 2014
Severance and other employee costs	$	3,089	$	31,492	$	(11,673	)	$	—		$	22,908
Other costs	173		14,254		(13,699		)	—			728
Accelerated depreciation	—		2,390		—			(2,390		)	—
Asset write down	—		915		—			(915		)	—
	$	3,262	$	49,051	$	(25,372	)	$	(3,305	)	$	23,636



(In thousands)	Balance at March 31, 2012		Cost Incurred		Payments			Less Non-Cash Adjustments			Restructuring Accrual Balance at March 30, 2013
Severance and other employee costs	$	1,461	$	6,214	$	(4,586	)	$	—		$	3,089
Facility related costs	533		431		(791		)	—			173
Asset write down	—		4,247		—			(4,247		)	—
	$	1,994	$	10,892	$	(5,377	)	$	(4,247	)	$	3,262

We deployed significant financial resources for these activities. Many of the activities necessary to complete the VCC initiatives include severance and other costs which qualify as restructuring expenses under ASC 420, Exit or Disposal Cost Obligations. We incurred $36.9 million in severance, asset write-offs and other restructuring charges in fiscal 2015. In addition, we also incurred $29.9 million of costs that do not constitute restructuring under ASC 420, which we refer to as "Transformation Costs". These costs consist primarily of expenditures directly related to our transformation activities including program management, integration and product line transfer teams, infrastructure related costs, accelerated depreciation and asset disposals.

The table below presents restructuring and transformation costs recorded in cost of goods sold, research and development, selling, general and administrative expenses and other (expense) income, net in our statements of income and comprehensive income for the periods presented. In fiscal 2015 and 2014, Transformation Costs were primarily related to our VCC initiatives. In fiscal 2013, the majority of our Transformation Costs were related to the integration of the whole blood acquisition.



Transformation costs
(in thousands)	March 28, 2015		March 29, 2014		March 30, 2013
Integration and other costs	$	24,061	$	30,701	$	60,878
Accelerated depreciation	930		4,203		687
Asset disposal	4,925		796		—
Total	$	29,916	$	35,700	$	61,565

Restructuring costs
(in thousands)	March 28, 2015		March 29, 2014		March 30, 2013
Severance and other employee costs	$	19,879	$	31,492	$	6,214
Other costs	15,362		14,254		431
Accelerated depreciation	1,326		2,390		—
Asset disposal	296		915		4,247
Total	$	36,863	$	49,051	$	10,892

Total restructuring and transformation	$	66,779	$	84,751	$	72,457

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	12 Months Ended
CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	Mar. 28, 2015
Capitalization of Software and Development Costs [Abstract]
CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS The cost of software that is developed or obtained for internal use is accounted for pursuant to ASC Topic 350, Intangibles — Goodwill and Other. Pursuant to ASC Topic 350, the Company capitalizes costs incurred during the application development stage of software developed for internal use, and expenses costs incurred during the preliminary project and the post-implementation operation stages of development. The costs capitalized for each project are included in intangible assets in the consolidated financial statements. For costs incurred related to the development of software to be sold, leased, or otherwise marketed, the Company applies the provisions of ASC Topic 985-20, Software - Costs of Software to be Sold, Leased or Marketed, which specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers. We capitalized $9.5 million and $6.0 million in software development costs for ongoing initiatives during the fiscal years ended March 28, 2015 and March 29, 2014, respectively. At March 28, 2015 and March 29, 2014, we have a total of $39.7 million and $31.7 million of software costs capitalized, of which $7.9 million and $15.6 million are related to in process software development initiatives, respectively. In connection with these development activities, we capitalized interest of $0.2 million and $0.4 million in fiscal 2015 and 2014, respectively. We amortize capitalized costs when the products are released for sale. During fiscal 2015, $15.7 million of capitalized costs were placed into service, compared to $10.4 million of capitalized costs placed into service during fiscal 2014. Amortization of capitalized software development cost expense was $3.2 million, $1.1 million and $0.9 million for fiscal 2015, 2014 and 2013 respectively.

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References + Details

SUMMARY OF QUARTERLY DATA (UNAUDITED)

12 Months Ended

Mar. 28, 2015

Quarterly Financial Data [Abstract]

SUMMARY OF QUARTERLY DATA (UNAUDITED)



(In thousands)	Three months ended
Fiscal 2015	June 28, 2014			September 27, 2014		December 27, 2014		March 28, 2015
Net revenues	$	224,488		$	227,580	$	231,827	$	226,478
Gross profit	$	106,278		$	108,114	$	111,661	$	108,365
Operating (loss) income	$	(1,666	)	$	12,407	$	18,260	$	11,539
Net (loss) income	$	(3,649	)	$	7,487	$	15,988	$	(2,929	)
Per share data:
Net (loss) Income:
Basic	$	(0.07	)	$	0.15	$	0.31	$	(0.06	)
Diluted	$	(0.07	)	$	0.14	$	0.31	$	(0.06	)

	Three months ended
Fiscal 2014	June 29, 2013			September 28, 2013		December 28, 2013		March 29, 2014
Net revenues	$	219,543		$	235,755	$	242,120	$	241,091
Gross profit	$	111,412		$	119,884	$	121,629	$	115,440
Operating (loss) income	$	(6,608	)	$	23,120	$	17,554	$	12,366
Net (loss) income	$	(7,874	)	$	16,548	$	16,290	$	10,184
Per share data:
Net (loss) Income:
Basic	$	(0.15	)	$	0.32	$	0.31	$	0.20
Diluted	$	(0.15	)	$	0.32	$	0.31	$	0.19

ACCUMULATED OTHER COMPREHENSIVE INCOME

12 Months Ended

Mar. 28, 2015

Stockholders' Equity Note [Abstract]

ACCUMULATED OTHER COMPREHENSIVE INCOME

The following is a roll-forward of the components of Accumulated Other Comprehensive Income, net of tax, for the years ended March 28, 2015 and March 29, 2014:



(In thousands)	Foreign currency			Defined benefit plans			Net Unrealized Gain/loss on Derivatives			Total
Balance as of March 30, 2013	$	4,133		$	(5,073	)	$	6,373		$	5,433
Other comprehensive (loss)/income before reclassifications	(935		)	223			5,001			4,289
Amounts reclassified from Accumulated Other Comprehensive Income	—			258			(8,570		)	(8,312		)
Net current period other comprehensive (loss)/income	(935		)	481			(3,569		)	(4,023		)
Balance as of March 29, 2014	$	3,198		$	(4,592	)	$	2,804		$	1,410
Other comprehensive (loss)/income before reclassifications	(23,710		)	(4,410		)	11,371			(16,749		)
Amounts reclassified from Accumulated Other Comprehensive Income	—			79			(6,464		)	(6,385		)
Net current period other comprehensive (loss)/income	(23,710		)	(4,331		)	4,907			(23,134		)
Balance as of March 28, 2015	$	(20,512	)	$	(8,923	)	$	7,711		$	(21,724	)

The details about the amount reclassified from Accumulated Other Comprehensive Income for the years ended March 28, 2015 and March 29, 2014 are as follows:



(In thousands)	Amounts Reclassified from Other Comprehensive Income						Affected Line in the Statement of Income
Derivative instruments reclassified to income statement	Year ended March 28, 2015			Year ended March 29, 2014
Realized net gain on derivatives	$	6,736		$	8,960		Revenue, cost of goods sold, other income
Income tax effect	(272		)	(390		)	Provision for income taxes
Net of taxes	$	6,464		$	8,570

Pension items reclassified to income statement
Realized net loss on pension assets	$	123		$	317		Other income
Income tax effect	(44		)	(59		)	Provision for income taxes
Net of taxes	$	79		$	258

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

VALUATION AND QUALIFYING ACCOUNTS

12 Months Ended

Mar. 28, 2015

Valuation and Qualifying Accounts [Abstract]

VALUATION AND QUALIFYING ACCOUNTS

SCHEDULE II

HAEMONETICS CORPORATION

VALUATION AND QUALIFYING ACCOUNTS



(In thousands)	Balance at Beginning of Fiscal Year		Charged to Costs and Expenses		Write-Offs (Net of Recoveries)			Balance at End of Fiscal Year
For Year Ended March 28, 2015
Allowance for Doubtful Accounts	$	1,676	$	399	$	(326	)	$	1,749
For Year Ended March 29, 2014
Allowance for Doubtful Accounts	$	1,727	$	186	$	(237	)	$	1,676
For Year Ended March 30, 2013
Allowance for Doubtful Accounts	$	1,480	$	446	$	(199	)	$	1,727

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies)

12 Months Ended

Mar. 28, 2015

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Fiscal Year

Our fiscal year ends on the Saturday closest to the last day of March. Fiscal years 2015, 2014 and 2013 each includes 52 weeks with each quarter having 13 weeks.

Principles of Consolidation

Use of Estimates

Reclassifications

Certain reclassifications have been made to prior years' amounts to conform to the current year's presentation.

Translation of Foreign Currencies

Cash and Cash Equivalents

Allowance for Doubtful Accounts

Property, Plant and Equipment



Asset Classification		Estimated Useful Lives
Building		30 Years
Building improvements		5-20 Years
Plant equipment and machinery		3-15 Years
Office equipment and information technology		3-10 Years
Haemonetics equipment		3-7 Years


•	Purchase and consumption of a certain level of disposable products


•	Payment of monthly rental fees


•	An asset utilization performance metric, such as performing a minimum level of procedures per month per device

Goodwill and Other Intangible Assets

Accounting for the Costs of Computer Software to be Sold, Leased, or Otherwise Marketed

Other Liabilities

Other liabilities represent items payable or expected to settle within the next twelve months. The items included in the fiscal year end balances were:



(In thousands)	March 28, 2015		March 29, 2014
VAT liabilities	$	4,205	$	7,114
Forward contracts	2,657		1,255
Deferred revenue	22,362		24,777
All other	34,987		26,564
Total	$	64,211	$	59,710

Research and Development Expenses

All research and development costs are expensed as incurred.

Advertising Costs

All advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the consolidated statements of income.

Accounting for Shipping and Handling Costs

Income Taxes

Derivative Instruments

Stock-Based Compensation

To calculate the grant-date fair value of our stock options we use the Black-Scholes option-pricing model and for performance share units and market stock units we use Monte Carlo Simulation models.

Valuation of Acquisitions

Concentration of Credit Risk and Significant Customers

Recent Accounting Pronouncements

Standards to be Implemented

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables)

12 Months Ended

Mar. 28, 2015

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Schedule of Property, Plant and Equipment Estimated Useful Lives



Asset Classification		Estimated Useful Lives
Building		30 Years
Building improvements		5-20 Years
Plant equipment and machinery		3-15 Years
Office equipment and information technology		3-10 Years
Haemonetics equipment		3-7 Years

Schedule of Other Accrued Liabilities

The items included in the fiscal year end balances were:



(In thousands)	March 28, 2015		March 29, 2014
VAT liabilities	$	4,205	$	7,114
Forward contracts	2,657		1,255
Deferred revenue	22,362		24,777
All other	34,987		26,564
Total	$	64,211	$	59,710

ACQUISITIONS (Tables)

12 Months Ended

Mar. 28, 2015

Business Combinations [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The final purchase price allocation is as follows:



Asset class	Amounts recognized as of March 29, 2014
Acquired technology	$	22,800
Trade name	1,900
Customer relationship	600
Goodwill	6,425
Total	$	31,725

We completed the allocation of the purchase price to the estimated fair value of the acquired assets and liabilities in June 2013 and is summarized below:



Asset class	Amounts Recognized as of March 30, 2013
(In thousands)
Inventories	$	49,917
Property, plant and equipment	85,984
Intangible assets	188,500
Other assets/liabilities, net	(6,166		)
Goodwill	216,940
Fair value of net assets acquired	$	535,175

Business Acquisition, Pro Forma Information



(In thousands, except per share amounts)	March 30, 2013
Net Sales	$	963,923
Net Income	$	56,540
Basic EPS	$	1.10
Diluted EPS	$	1.08

PRODUCT WARRANTIES (Tables)

12 Months Ended

Mar. 28, 2015

Product Warranties Disclosures [Abstract]

Schedule of Product Warranty Liability

We estimate our potential warranty expense based on our historical warranty experience, and we periodically assess the adequacy of our warranty accrual and make adjustments as necessary.



(In thousands)	March 28, 2015			March 29, 2014
Warranty accrual as of the beginning of the year	$	590		$	673
Warranty provision	1,199			1,340
Warranty spending	(1,258		)	(1,423		)
Warranty accrual as of the end of the year	$	531		$	590

INVENTORIES (Tables)

12 Months Ended

Mar. 28, 2015

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method.



(In thousands)	March 28, 2015		March 29, 2014
Raw materials	$	71,794	$	72,508
Work-in-process	12,462		7,383
Finished goods	126,821		117,770
Total Inventory	$	211,077	$	197,661

GOODWILL AND INTANGIBLE ASSETS (Tables)

12 Months Ended

Mar. 28, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The changes in the carrying amount of goodwill for fiscal 2015 and 2014 are as follows:



(In thousands)
Carrying amount as of March 30, 2013	$	330,474
Hemerus acquisition	6,425
Effects of change in foreign currency exchange rates	(131		)
Carrying amount as of March 29, 2014	$	336,768
Effects of change in foreign currency exchange rates	(2,458		)
Carrying amount as of March 28, 2015	$	334,310

Schedule of Amoritized Intangibles

The gross carrying amount of intangible assets and the related accumulated amortization as of March 28, 2015 and March 29, 2014 is as follows:



(In thousands)	Gross Carrying Amount		Accumulated Amortization		Net		Weighted Average Useful Life
							(In years)
As of March 28, 2015
Patents	$	10,473	$	7,373	$	3,100	9
Capitalized software	39,690		5,654		34,036		7
Other developed technology	124,573		46,474		78,099		12
Customer contracts and related relationships	195,985		70,440		125,545		10
Trade names	7,042		3,234		3,808		11
Total intangibles	$	377,763	$	133,175	$	244,588	10



(In thousands)	Gross Carrying Amount		Accumulated Amortization		Net		Weighted Average Useful Life
							(In years)
As of March 29, 2014
Patents	$	9,543	$	7,039	$	2,504	9
Capitalized software	31,750		2,414		29,336		4
Other developed technology	123,525		36,632		86,893		12
Customer contracts and related relationships	200,694		52,741		147,953		12
Trade names	7,341		2,868		4,473		11
Total intangibles	$	372,853	$	101,694	$	271,159	11

Schedule of Future Amortization Expense

Future annual amortization expense on intangible assets is estimated to be as follows:



Fiscal Year	Amount (in thousands)
2016	$	33,752
2017	$	32,998
2018	$	32,165
2019	$	30,470
2020 and thereafter	$	104,544

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Tables)

12 Months Ended

Mar. 28, 2015

Derivatives and Fair Value Measurements [Abstract]

Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments



Derivative Instruments	Amount of Gain/(Loss) Recognized in OCI (Effective Portion)			Amount of Gain/(Loss) Reclassified from OCI into Earnings (Effective Portion)		Location in Statement of Operations	Amount of Gain/(Loss) Excluded from Effectiveness Testing (*)			Location in Statement of Operations
(In thousands)
Designated foreign currency hedge contracts, net of tax	$	12,249		$	6,464	Net revenues, COGS, and SG&A	$	(170	)	Other income (expense), net
Non-designated foreign currency hedge contracts	—			—			$	7,510		Other income (expense)
Designated interest rate swaps, net of tax	$	(878	)	$	—	Interest income (expense), net	$	—



(*)		We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.

Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets



(In thousands)	Location in Balance Sheet	Balance as of March 28, 2015		Balance as of March 29, 2014
Derivative Assets:
Designated foreign currency hedge contracts	Other current assets	$	9,740	$	2,574
Designated interest rate swaps	Other current assets	—		1,250
		$	9,740	$	3,824
Derivative Liabilities:
Designated foreign currency hedge contracts	Other current liabilities	$	2,499	$	1,255
Designated interest rate swaps	Other current liabilities	159		—
		$	2,658	$	1,255

Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of March 28, 2015 and March 29, 2014:



As of March 28, 2015	Quoted Market Prices for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
	(In thousands)		(In thousands)		(In thousands)		(In thousands)
Assets
Money market funds	$	119,946	$	—	$	—	$	119,946
Foreign currency hedge contracts	—		9,740		—		9,740
	$	119,946	$	9,740	$	—	$	129,686
Liabilities
Foreign currency hedge contracts	$	—	$	2,499	$	—	$	2,499
Interest rate swap	—		159		—		159
Contingent consideration	—		—		4,727		4,727
	$	—	$	2,658	$	4,727	$	7,385



As of March 29, 2014	Quoted Market Prices for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
	(In thousands)		(In thousands)		(In thousands)		(In thousands)
Assets
Money market funds	$	135,378	$	—	$	—	$	135,378
Forward currency hedge contracts	—		2,574		—		2,574
Interest rate swap	—		1,250		—		1,250
	$	135,378	$	3,824	$	—	$	139,202
Liabilities
Forward currency hedge contracts	$	—	$	1,255	$	—	$	1,255
Contingent consideration	—		—		7,645		7,645
	$	—	$	1,255	$	7,645	$	8,900

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation



(In thousands)	Fair value measurements using significant unobservable inputs (Level 3)
Contingent consideration as of March 29, 2014	$	7,645
Fair value adjustment	(2,918		)
Ending balance	$	4,727

NOTES PAYABLE AND LONG-TERM DEBT (Tables)

12 Months Ended

Mar. 28, 2015

Notes Payable and Long-Term Debt [Abstract]

Schedule of Notes Payable and Long-Term Debt

Notes payable and long-term debt consisted of the following:



(In thousands)	March 28, 2015			March 29, 2014
Term loan, net of financing fees	$	426,814		$	435,338
Real estate mortgage	851			1,906
Bank loans and other borrowings	226			443
Less current portion	(21,522		)	(45,630		)
Long-term debt	$	406,369		$	392,057

Schedule of Notes Payable and Long-Term Debt Maturities

The maturity profile of all gross long-term debt, exclusive of debt discounts, as of March 28, 2015 is presented below:



Fiscal year (in thousands)	Mortgage Obligation		Credit Facilities		Bank loans and other borrowings		Total
2016	$	851	$	21,342	$	144	$	22,337
2017	—		42,683		65		42,748
2018	—		45,054		17		45,071
2019	—		151,763		—		151,763
2020	—		168,564		—		168,564
	$	851	$	429,406	$	226	$	430,483

INCOME TAXES (Tables)

12 Months Ended

Mar. 28, 2015

Income Tax Disclosure [Abstract]

Schedule Domestic and Foreign Income Before Provision for Income Tax

Domestic and foreign income before provision for income tax is as follows:



(In thousands)	March 28, 2015			March 29, 2014			March 30, 2013
Domestic	$	(17,265	)	$	(6,859	)	$	17,360
Foreign	48,430			43,260			32,537
Total	$	31,165		$	36,401		$	49,897

Schedule of Income Tax Provision Components

The income tax provision contains the following components:



(In thousands)	March 28, 2015			March 29, 2014			March 30, 2013
Current
Federal	$	3,526		$	(4,896	)	$	3,795
State	898			873			1,324
Foreign	5,614			5,478			5,389
Total current	$	10,038		$	1,455		$	10,508
Deferred
Federal	1,227			(1,785		)	1,644
State	3,215			207			(229		)
Foreign	(212		)	1,376			(826		)
Total deferred	$	4,230		$	(202	)	$	589
Total	$	14,268		$	1,253		$	11,097

Schedule of Net Deferred Tax Asset

Tax affected, significant temporary differences comprising the net deferred tax liability are as follows:



(In thousands)	March 28, 2015			March 29, 2014
Depreciation	$	(23,733	)	$	(23,658	)
Amortization	(24,038		)	(18,618		)
Inventory	6,189			7,371
Hedging	84			321
Accruals, reserves and other	15,927			10,368
Net operating loss carry-forward	5,392			1,507
Stock based compensation	10,652			8,757
Tax credit carry-forward, net	8,678			2,660
Gross deferred taxes	$	(849	)	$	(11,292	)
Less valuation allowance	(16,027		)	(3,083		)
Net deferred tax liability	$	(16,876	)	$	(14,375	)

Schedule of Effective Income Tax Rate Reconciliation

The income tax provision from operations differs from tax provision computed at the 35.0% U.S. federal statutory income tax rate due to the following:



(In thousands)	March 28, 2015					March 29, 2014					March 30, 2013
Tax at federal statutory rate	$	10,907		35.0	%	$	12,739		35.0	%	$	17,464		35.0	%
Domestic manufacturing deduction	—			—	%	—			—	%	(504		)	(1.0	)%
Difference between U.S. and foreign tax	(6,929		)	(22.2	)%	(10,846		)	(29.8	)%	(5,584		)	(11.2	)%
State income taxes net of federal benefit	(818		)	(2.6	)%	(252		)	(0.7	)%	718			1.4	%
Change in uncertain tax positions	(1,762		)	(5.7	)%	(1,678		)	(4.6	)%	(580		)	(1.2	)%
Intercompany loan deduction	—			—	%	(2,185		)	(6.0	)%	—			—	%
Non-deductible expenses	1,237			4.0	%	1,035			2.8	%	1,178			2.4	%
Research credits	(1,000		)	(3.2	)%	(688		)	(1.9	)%	(799		)	(1.6	)%
Naked Credit	3,826			12.3	%	—			—	%	—			—	%
Valuation allowance	8,524			27.4	%	2,400			6.6	%	—			—	%
Other, net	283			0.8	%	728			2.0	%	(796		)	(1.6	)%
Income tax provision	$	14,268		45.8	%	$	1,253		3.4	%	$	11,097		22.2	%

Summary of Gross Unrecognized Tax Benefits

The following table summarizes the activity related to our gross unrecognized tax benefits for the fiscal years ended March 28, 2015, March 29, 2014 and March 30, 2013:



(In thousands)	March 28, 2015			March 29, 2014			March 30, 2013
Beginning Balance	$	5,604		$	6,930		$	6,885
Additions based upon positions related to the current year	—			—			1,192
Additions for tax positions of prior years	3,234			990			18
Settlements with taxing authorities	(338		)	—			(80		)
Closure of statute of limitations	(1,430		)	(2,316		)	(1,085		)
Ending Balance	$	7,070		$	5,604		$	6,930

COMMITMENTS AND CONTINGENCIES (Tables)

12 Months Ended

Mar. 28, 2015

Commitments and Contingencies Disclosure [Abstract]

Schedule of Approximate Future Basic Rental Commitments under Operating Leases

Approximate future basic rental commitments under operating leases as of March 28, 2015 are as follows (in thousands):



Fiscal Year Ending
(In thousands)
2016	$	6,797
2017	4,780
2018	3,758
2019	2,427
2020 and thereafter	11,585
	$	29,347

CAPITAL STOCK (Tables)

12 Months Ended

Mar. 28, 2015

Capital Stock [Abstract]

Schedule of Summary of Stock Option Activity

A summary of stock option activity for the fiscal year ended March 28, 2015 is as follows:



	Options Outstanding (shares)		Weighted Average Exercise Price per Share		Weighted Average Remaining Life (years)	Aggregate Intrinsic Value ($000’s)
Outstanding at March 29, 2014	3,834,372		$	32.93	4.19	$	9,436
Granted	592,024		34.87
Exercised	(500,103	)	26.14
Forfeited	(164,627	)	38.13
Outstanding at March 28, 2015	3,761,666		$	33.90	4.02	$	37,067

Exercisable at March 28, 2015	2,281,022		$	31.57	2.92	$	27,826

Vested or expected to vest at March 28, 2015	3,596,493		$	33.73	3.93	$	36,066

Schedule of Assumptions Utilized for Estimating Fair Value of Option Grants

The assumptions utilized for option grants during the periods presented are as follows:



	March 28, 2015		March 29, 2014		March 30, 2013
Volatility	22.5	%	24.8	%	26.4	%
Expected life (years)	4.9		4.9		4.9
Risk-free interest rate	1.5	%	1.3	%	0.8	%
Dividend yield	0.0	%	0.0	%	0.0	%

Schedule of Assumptions Used to Estimate Fair Value of Shares Purchased Under ESPP

The fair values of shares purchased under the Employee Stock Purchase Plan are estimated using the Black-Scholes single option-pricing model with the following weighted average assumptions:



	March 28, 2015		March 29, 2014		March 30, 2013
Volatility	23.7	%	22.9	%	24.9	%
Expected life (months)	6		6		6
Risk-free interest rate	0.1	%	0.1	%	0.2	%
Dividend Yield	0.0	%	0.0	%	0.0	%

The weighted average rates used to determine the net periodic benefit costs and projected benefit obligations were as follows:



	March 28, 2015		March 29, 2014		March 30, 2013
Discount rate	0.93	%	2.02	%	1.97	%
Rate of increased salary levels	1.65	%	1.57	%	1.42	%
Expected long-term rate of return on assets	1.68	%	1.94	%	1.92	%

Schedule of Performance Share Unit awards



			For Year Ended March 28, 2015
Performance Period	Award Fair Value as of October 22, 2014		Recognized Compensation Expense		Unrecognized Compensation Expense		Minimum Shares	Target Shares	Maximum Shares
	(Per share)		(In thousands)		(In thousands)
Oct 1, 2014 - Sept 30, 2017	$	35.09	$	662	$	3,869	—	129,130	258,260

Schedule of Summary of Restricted Stock Units Activity

A summary of performance stock units, restricted stock units and market stock units activity for the fiscal year ended March 28, 2015 is as follows:



	Shares		Weighted Average Market Value at Grant Date
Unvested at March 29, 2014	599,673		$	37.70
Awarded	351,666		$	35.18
Released	(110,048	)	$	36.65
Forfeited	(66,932	)	$	37.83
Unvested at March 28, 2015	774,359		$	36.70

EARNINGS PER SHARE ("EPS") (Tables)

12 Months Ended

Mar. 28, 2015

Earnings Per Share [Abstract]

Schedule of Earnings Per Share Reconciliation



(In thousands, except per share amounts)	March 28, 2015		March 29, 2014		March 30, 2013
Basic EPS
Net income	$	16,897	$	35,148	$	38,800
Weighted average shares	51,533		51,611		51,349
Basic income per share	$	0.33	$	0.68	$	0.76
Diluted EPS
Net income	$	16,897	$	35,148	$	38,800
Basic weighted average shares	51,533		51,611		51,349
Net effect of common stock equivalents	556		766		910
Diluted weighted average shares	52,089		52,377		52,259
Diluted income per share	$	0.32	$	0.67	$	0.74

PROPERTY, PLANT AND EQUIPMENT (Tables)

12 Months Ended

Mar. 28, 2015

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment

Property and equipment consisted of the following:



(In thousands)	March 28, 2015			March 29, 2014
Land	$	9,468		$	7,168
Building and building improvements	118,384			83,439
Plant equipment and machinery	220,793			236,539
Office equipment and information technology	118,810			111,925
Haemonetics equipment	264,307			262,784
Total	731,762			701,855
Less: accumulated depreciation and amortization	(409,814		)	(430,418		)
Property, plant and equipment, net	$	321,948		$	271,437

RETIREMENT PLANS (Tables)

12 Months Ended

Mar. 28, 2015

Compensation and Retirement Disclosure [Abstract]

Schedule of Components of Net Periodic Benefit Costs of Defined Benefit Pension Plans



(In thousands)	March 28, 2015			March 29, 2014			March 30, 2013
Service cost	$	2,979		$	3,351		$	2,759
Interest cost on benefit obligation	686			623			639
Expected (return)/loss on plan assets	(449		)	(435		)	(413		)
Actuarial loss/(gain)	107			88			196
Amortization of unrecognized prior service cost	(29		)	182			(14		)
Amortization of unrecognized transition obligation	45			47			48
Totals	$	3,339		$	3,856		$	3,215

Schedule of Activity Under Defined Benefit Plans

The activity under those defined benefit plans are as follows:



(In thousands)	March 28, 2015			March 29, 2014
Change in Benefit Obligation:
Benefit Obligation, beginning of year	$	(32,621	)	$	(30,126	)
Service cost	(2,979		)	(3,351		)
Interest cost	(686		)	(623		)
Benefits paid	4,902			4,474
Actuarial (loss)/gain	(6,883		)	55
Employee and plan participants contribution	(2,978		)	(2,963		)
Plan Amendments	114			419
Foreign currency changes	564			(506		)
Benefit obligation, end of year	$	(40,567	)	$	(32,621	)
Change in Plan Assets:
Fair value of plan assets, beginning of year	$	19,981		$	19,577
Company contributions	2,112			2,241
Benefits paid	(4,621		)	(4,641		)
Gain/(Loss) on plan assets	506			100
Employee and plan participants contributions	2,851			3,087
Foreign currency changes	2,336			(383		)
Fair value of Plan Assets, end of year	$	23,165		$	19,981
Funded Status	$	(17,402	)	$	(12,640	)
Unrecognized net actuarial loss/(gain)	11,096			5,899
Unrecognized initial obligation	64			94
Unrecognized prior service cost	(459		)	(422		)
Net amount recognized	$	(6,701	)	$	(7,069	)

Schedule of Components of Change Recorded in Accumulated Other Comprehensive Income Related to Defined Benefit Plans, Net of Tax

The components of the change recorded in our accumulated other comprehensive income related to our defined benefit plans, net of tax, are as follows (in thousands):



Balance, March 31, 2012	$	(4,253	)
Obligation at transition	556
Actuarial loss	(1,237		)
Prior service cost	(139		)
Balance as of March 30, 2013	$	(5,073	)
Obligation at transition	172
Actuarial loss	(129		)
Prior service cost	438
Balance as of March 29, 2014	$	(4,592	)
Obligation at transition	(19		)
Actuarial loss	(6,198		)
Prior service cost	1,886
Balance as of March 28, 2015	$	(8,923	)

Schedule of Weighted Average Rates Used to Determine Net Periodic Benefit Costs

The fair values of shares purchased under the Employee Stock Purchase Plan are estimated using the Black-Scholes single option-pricing model with the following weighted average assumptions:



	March 28, 2015		March 29, 2014		March 30, 2013
Volatility	23.7	%	22.9	%	24.9	%
Expected life (months)	6		6		6
Risk-free interest rate	0.1	%	0.1	%	0.2	%
Dividend Yield	0.0	%	0.0	%	0.0	%

The weighted average rates used to determine the net periodic benefit costs and projected benefit obligations were as follows:



	March 28, 2015		March 29, 2014		March 30, 2013
Discount rate	0.93	%	2.02	%	1.97	%
Rate of increased salary levels	1.65	%	1.57	%	1.42	%
Expected long-term rate of return on assets	1.68	%	1.94	%	1.92	%

Schedule of Estimated Future Benefit Payments

Estimated future benefit payments during the next five years and in the aggregate for the five fiscal years thereafter, are as follows (in thousands):



Expected Benefit Payments
Fiscal Year 2016	$	1,735
Fiscal Year 2017	$	1,654
Fiscal Year 2018	$	1,502
Fiscal Year 2019	$	1,610
Fiscal Year 2020	$	1,732
Fiscal Year 2021-2024	$	7,493

SEGMENT INFORMATION (Tables)

12 Months Ended

Mar. 28, 2015

Segment Reporting [Abstract]

Schedule of Revenues from External Customers

Enterprise Wide Disclosures About Product and Services

Year Ended (in thousands)



March 28, 2015	United States		Other North America		Total North America		Japan		Other Asia		Total Europe		Total Consolidated
Net revenues	$	494,788	$	9,617	$	504,405	$	88,298	$	102,095	$	215,575	$	910,373
Total Assets	$	810,159	$	240,610	$	1,050,769	$	41,621	$	79,084	$	313,943	$	1,485,417
Long-Lived Assets	$	532,187	$	212,548	$	744,735	$	9,230	$	46,857	$	114,318	$	915,140



March 29, 2014	United States		Other North America		Total North America		Japan		Other Asia		Total Europe		Total Consolidated
Net revenues	$	500,719	$	9,557	$	510,276	$	108,679	$	94,762	$	224,792	$	938,509
Total Assets	$	810,409	$	225,998	$	1,036,407	$	53,207	$	53,055	$	371,509	$	1,514,178
Long-Lived Assets	$	519,396	$	211,624	$	731,020	$	11,522	$	17,269	$	131,391	$	891,202



March 30, 2013	United States		Other North America		Total North America		Japan		Other Asia		Total Europe		Total Consolidated
Net revenues	$	454,874	$	6,851	$	461,725	$	120,726	$	84,860	$	224,679	$	891,990
Total Assets	$	830,754	$	225,849	$	1,056,603	$	44,189	$	41,037	$	320,088	$	1,461,917
Long-Lived Assets	$	503,606	$	209,439	$	713,045	$	12,977	$	8,076	$	117,717	$	851,815

Enterprise Wide Disclosures about Product and Services

Revenues from External Customers:



(In thousands)	March 28, 2015		March 29, 2014		March 30, 2013
Disposable revenues
Plasma disposables	$	319,190	$	291,895	$	268,900
Blood center disposables
Platelet	152,588		156,643		169,602
Red cell	42,700		42,378		49,733
Whole blood	143,905		190,698		138,436
	339,193		389,719		357,771
Hospital disposables
Surgical	62,540		66,876		73,508
OrthoPAT	20,316		25,042		30,230
Diagnostics	42,187		33,302		27,356
	125,043		125,220		131,094
Disposables revenue	783,426		806,834		757,765
Software solutions	72,185		70,441		69,952
Equipment & other	54,762		61,234		64,273
Total revenues	$	910,373	$	938,509	$	891,990

RESTRUCTURING (Tables)

12 Months Ended

Mar. 28, 2015

Restructuring and Related Activities [Abstract]

Schedule of Restructuring and Transformation Costs by Type of Cost

The following summarizes the restructuring activity for the fiscal year ended March 28, 2015, March 29, 2014, and March 30, 2013, respectively:



(In thousands)	Balance at March 29, 2014		Cost Incurred		Payments			Less Non-Cash Adjustments			Restructuring Accrual Balance at March 28, 2015
Severance and other employee costs	$	22,908	$	19,879	$	(26,394	)	$	—		$	16,393
Other costs	728		15,362		(15,871		)	—			219
Accelerated depreciation	—		1,326		—			(1,326		)	—
Asset write-down	—		296		—			(296		)	—
	$	23,636	$	36,863	$	(42,265	)	$	(1,622	)	$	16,612



(In thousands)	Balance at March 30, 2013		Cost Incurred		Payments			Less Non-Cash Adjustments			Restructuring Accrual Balance at March 29, 2014
Severance and other employee costs	$	3,089	$	31,492	$	(11,673	)	$	—		$	22,908
Other costs	173		14,254		(13,699		)	—			728
Accelerated depreciation	—		2,390		—			(2,390		)	—
Asset write down	—		915		—			(915		)	—
	$	3,262	$	49,051	$	(25,372	)	$	(3,305	)	$	23,636



(In thousands)	Balance at March 31, 2012		Cost Incurred		Payments			Less Non-Cash Adjustments			Restructuring Accrual Balance at March 30, 2013
Severance and other employee costs	$	1,461	$	6,214	$	(4,586	)	$	—		$	3,089
Facility related costs	533		431		(791		)	—			173
Asset write down	—		4,247		—			(4,247		)	—
	$	1,994	$	10,892	$	(5,377	)	$	(4,247	)	$	3,262



Transformation costs
(in thousands)	March 28, 2015		March 29, 2014		March 30, 2013
Integration and other costs	$	24,061	$	30,701	$	60,878
Accelerated depreciation	930		4,203		687
Asset disposal	4,925		796		—
Total	$	29,916	$	35,700	$	61,565

Restructuring costs
(in thousands)	March 28, 2015		March 29, 2014		March 30, 2013
Severance and other employee costs	$	19,879	$	31,492	$	6,214
Other costs	15,362		14,254		431
Accelerated depreciation	1,326		2,390		—
Asset disposal	296		915		4,247
Total	$	36,863	$	49,051	$	10,892

Total restructuring and transformation	$	66,779	$	84,751	$	72,457

SUMMARY OF QUARTERLY DATA (UNAUDITED) (Tables)

12 Months Ended

Mar. 28, 2015

Quarterly Financial Data [Abstract]

Schedule of Quarterly Data



(In thousands)	Three months ended
Fiscal 2015	June 28, 2014			September 27, 2014		December 27, 2014		March 28, 2015
Net revenues	$	224,488		$	227,580	$	231,827	$	226,478
Gross profit	$	106,278		$	108,114	$	111,661	$	108,365
Operating (loss) income	$	(1,666	)	$	12,407	$	18,260	$	11,539
Net (loss) income	$	(3,649	)	$	7,487	$	15,988	$	(2,929	)
Per share data:
Net (loss) Income:
Basic	$	(0.07	)	$	0.15	$	0.31	$	(0.06	)
Diluted	$	(0.07	)	$	0.14	$	0.31	$	(0.06	)

	Three months ended
Fiscal 2014	June 29, 2013			September 28, 2013		December 28, 2013		March 29, 2014
Net revenues	$	219,543		$	235,755	$	242,120	$	241,091
Gross profit	$	111,412		$	119,884	$	121,629	$	115,440
Operating (loss) income	$	(6,608	)	$	23,120	$	17,554	$	12,366
Net (loss) income	$	(7,874	)	$	16,548	$	16,290	$	10,184
Per share data:
Net (loss) Income:
Basic	$	(0.15	)	$	0.32	$	0.31	$	0.20
Diluted	$	(0.15	)	$	0.32	$	0.31	$	0.19

ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)

12 Months Ended

Mar. 28, 2015

Stockholders' Equity Note [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

The following is a roll-forward of the components of Accumulated Other Comprehensive Income, net of tax, for the years ended March 28, 2015 and March 29, 2014:



(In thousands)	Foreign currency			Defined benefit plans			Net Unrealized Gain/loss on Derivatives			Total
Balance as of March 30, 2013	$	4,133		$	(5,073	)	$	6,373		$	5,433
Other comprehensive (loss)/income before reclassifications	(935		)	223			5,001			4,289
Amounts reclassified from Accumulated Other Comprehensive Income	—			258			(8,570		)	(8,312		)
Net current period other comprehensive (loss)/income	(935		)	481			(3,569		)	(4,023		)
Balance as of March 29, 2014	$	3,198		$	(4,592	)	$	2,804		$	1,410
Other comprehensive (loss)/income before reclassifications	(23,710		)	(4,410		)	11,371			(16,749		)
Amounts reclassified from Accumulated Other Comprehensive Income	—			79			(6,464		)	(6,385		)
Net current period other comprehensive (loss)/income	(23,710		)	(4,331		)	4,907			(23,134		)
Balance as of March 28, 2015	$	(20,512	)	$	(8,923	)	$	7,711		$	(21,724	)

Reclassification out of Accumulated Other Comprehensive Income

The details about the amount reclassified from Accumulated Other Comprehensive Income for the years ended March 28, 2015 and March 29, 2014 are as follows:



(In thousands)	Amounts Reclassified from Other Comprehensive Income						Affected Line in the Statement of Income
Derivative instruments reclassified to income statement	Year ended March 28, 2015			Year ended March 29, 2014
Realized net gain on derivatives	$	6,736		$	8,960		Revenue, cost of goods sold, other income
Income tax effect	(272		)	(390		)	Provision for income taxes
Net of taxes	$	6,464		$	8,570

Pension items reclassified to income statement
Realized net loss on pension assets	$	123		$	317		Other income
Income tax effect	(44		)	(59		)	Provision for income taxes
Net of taxes	$	79		$	258

DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION (Details)	Nov. 30, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Stock split in form of dividend, conversion ratio	2

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details)	12 Months Ended
	Mar. 28, 2015 USD ($) Customers	Mar. 29, 2014 USD ($) Customers	Mar. 30, 2013 USD ($) Customers
Summary of Significant Accounting Pronouncements [Line Items]
Term of each fiscal year	1 year	1 year	1 year
Term of each fiscal quarter	91 days	91 days	91 days
Cash and cash equivalents maximum maturity period	3 months
Goodwill impairment	$ 0	$ 0	$ 0
Intangible asset impairment	0	0	0
Other Liabilities
VAT liabilities	4,205,000	7,114,000
Forward contracts	2,657,000	1,255,000
Deferred revenue	22,362,000	24,777,000
All other	34,987,000	26,564,000
Other current liabilities	64,211,000	59,710,000
Advertising expense	4,500,000	3,600,000	4,600,000
Foreign currency losses	$ 1,100,000	$ 500,000	$ 800,000
Building
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life	30 years
Sales [Member] \| Customer Concentration Risk [Member]
Other Liabilities
Concentration risk, number of customers \| Customers	0	0
Japanese Red Cross Society [Member] \| Sales [Member] \| Customer Concentration Risk [Member]
Other Liabilities
Concentration risk, number of customers \| Customers			1
Credit risk, accounts receivable			$ 90,100,000
Minimum
Summary of Significant Accounting Pronouncements [Line Items]
Software capitalization term	5 years
Minimum \| Building improvements
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life	5 years
Minimum \| Plant equipment and machinery
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life	3 years
Minimum \| Office equipment and information technology
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life	3 years
Minimum \| Haemonetics equipment
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life	3 years
Maximum
Summary of Significant Accounting Pronouncements [Line Items]
Software capitalization term	10 years
Maximum \| Building improvements
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life	20 years
Maximum \| Plant equipment and machinery
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life	15 years
Maximum \| Office equipment and information technology
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life	10 years
Maximum \| Haemonetics equipment
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life	7 years

ACQUISITIONS (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended								12 Months Ended
	Apr. 30, 2013	Aug. 01, 2012	Mar. 28, 2015	Dec. 27, 2014	Sep. 27, 2014	Jun. 28, 2014	Mar. 29, 2014	Dec. 28, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Allocation of purchase price
Goodwill			$ 334,310				$ 336,768				$ 334,310	$ 336,768	$ 330,474
Amortization expense											33,500	29,200	22,100
Net revenues			226,478	$ 231,827	$ 227,580	$ 224,488	241,091	$ 242,120	$ 235,755	$ 219,543	910,373	938,509	891,990
Whole blood
Allocation of purchase price
Net revenues											143,905	190,698	138,436
Term Loan
Allocation of purchase price
Face amount of debt			429,400								429,400
Hemerus Medical, LLC [Member]
Business Acquisition [Line Items]
Consideration paid	$ 24,100
Allocation of purchase price
Goodwill							6,425					6,425
Fair value of net assets acquired							31,725					31,725
Amortization expense											2,500	2,300
Hemerus Medical, LLC [Member] \| Acquired technology
Allocation of purchase price
Intangible assets							22,800					22,800
Hemerus Medical, LLC [Member] \| Trade names
Allocation of purchase price
Intangible assets							1,900					1,900
Hemerus Medical, LLC [Member] \| Customer relationship
Allocation of purchase price
Intangible assets							600					600
Hemerus Medical, LLC [Member] \| FDA Approval of SOLX [Member]
Business Acquisition [Line Items]
Contingent consideration, maximum	3,000
Allocation of purchase price
Contingent consideration amount owed			$ 4,727				$ 7,645				4,727	7,645
Hemerus Medical, LLC [Member] \| Future Sales of SOLX [Member]
Business Acquisition [Line Items]
Contingent consideration, maximum	$ 14,000
Pall Corporation [Member]
Business Acquisition [Line Items]
Consideration paid		$ 535,200
Allocation of purchase price
Inventories													49,917
Property, plant and equipment													85,984
Intangible assets													188,500
Other assets/liabilities, net													(6,166)
Goodwill													216,940
Fair value of net assets acquired													535,175
Consideration transfered in shares		500
Net Sales													963,923
Net Income													$ 56,540
Basic EPS													$ 1.10
Diluted EPS													$ 1.08
Pall Corporation [Member] \| Term Loan
Allocation of purchase price
Face amount of debt		$ 475,000
Pall Corporation [Member] \| Acquired technology
Allocation of purchase price
Intangible assets													$ 61,000
Pall Corporation [Member] \| Customer relationship
Allocation of purchase price
Intangible assets													127,500
Useful life		8 years
Pall Corporation [Member] \| Acquired Technology and Customer Relationships
Allocation of purchase price
Amortization expense											$ 18,800	$ 15,700	$ 10,500
Useful life		12 years
Pall Corporation [Member] \| Replication and Delivery of Certain Manufacturing Assets [Member]
Business Acquisition [Line Items]
Contingent consideration, maximum		$ 15,000

PRODUCT WARRANTIES (Schedule of Product Warranty Liability) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014
Product Warranties Disclosures [Abstract]
General warranty period on parts and labor	1 year
Product Warranties [Roll Forward]
Warranty accrual as of the beginning of the year	$ 590	$ 673
Warranty provision	1,199	1,340
Warranty spending	(1,258)	(1,423)
Warranty accrual as of the end of the year	$ 531	$ 590

INVENTORIES (Schedule of Inventories) (Details) - USD ($) $ in Thousands	Mar. 28, 2015	Mar. 29, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 71,794	$ 72,508
Work-in-process	12,462	7,383
Finished goods	126,821	117,770
Total Inventory	$ 211,077	$ 197,661

GOODWILL AND INTANGIBLE ASSETS Schedule of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014
Goodwill [Roll Forward]
Goodwill, carrying amount	$ 336,768	$ 330,474
Hemerus acquisition		6,425
Effects of change in foreign currency exchange rates	(2,458)	(131)
Goodwill, carrying amount	$ 334,310	$ 336,768

GOODWILL AND INTANGIBLE ASSETS Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Intangible Assets
Gross Carrying Amount	$ 377,763	$ 372,853
Accumulated Amortization	133,175	101,694
Net	$ 244,588	$ 271,159
Weighted average useful life	10 years	11 years
Aggregate amortization expense	$ 33,500	$ 29,200	$ 22,100
Future amortization expense, year one	33,752
Future amortization expense, year two	32,998
Future amortization expense, year three	32,165
Future amortization expense, year four	30,470
Future amortization expense, year five	104,544
Patents
Intangible Assets
Gross Carrying Amount	10,473	9,543
Accumulated Amortization	7,373	7,039
Net	$ 3,100	$ 2,504
Weighted average useful life	9 years	9 years
Capitalized software
Intangible Assets
Gross Carrying Amount	$ 39,690	$ 31,750
Accumulated Amortization	5,654	2,414
Net	$ 34,036	$ 29,336
Weighted average useful life	7 years	4 years
Other developed technology
Intangible Assets
Gross Carrying Amount	$ 124,573	$ 123,525
Accumulated Amortization	46,474	36,632
Net	$ 78,099	$ 86,893
Weighted average useful life	12 years	12 years
Customer contracts and related relationships
Intangible Assets
Gross Carrying Amount	$ 195,985	$ 200,694
Accumulated Amortization	70,440	52,741
Net	$ 125,545	$ 147,953
Weighted average useful life	10 years	12 years
Trade names
Intangible Assets
Gross Carrying Amount	$ 7,042	$ 7,341
Accumulated Amortization	3,234	2,868
Net	$ 3,808	$ 4,473
Weighted average useful life	11 years	11 years
Minimum
Intangible Assets
Weighted average useful life	2 years
Maximum
Intangible Assets
Weighted average useful life	19 years

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Narrative) (Details) $ in Thousands	12 Months Ended
	Mar. 28, 2015 USD ($)	Mar. 29, 2014 USD ($)	Mar. 30, 2013 USD ($)	Dec. 29, 2012	Dec. 21, 2012 USD ($) swap	Aug. 01, 2012 USD ($)
Derivative [Line Items]
Deferred tax benefit	$ 4,230	$ (202)	$ 589
Variable rate basis	LIBOR
Hemerus Medical, LLC [Member] \| FDA Approval of SOLX [Member]
Derivative [Line Items]
Contingent consideration amount owed	$ 4,727	7,645
Hemerus Medical, LLC [Member] \| FDA Approval of SOLX [Member] \| Fair Value Adjustment
Derivative [Line Items]
Contingent consideration amount owed	(2,918)
Term Loan
Derivative [Line Items]
Face amount of debt	$ 429,400
Term Loan \| Pall Corporation [Member]
Derivative [Line Items]
Adjusted libor rounding percentage						6.25%
Face amount of debt						$ 475,000
Credit Agreement
Derivative [Line Items]
Adjusted libor rounding percentage				0.625%
Variable rate basis	1-month USD-LIBOR-BBA
Foreign Exchange Contract
Derivative [Line Items]
Percentage of sales generated outside the US	45.60%
Maturity period for foreign currency contracts (in years)	1 year
Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative [Line Items]
Designated foreign currency hedge contracts outstanding	$ 145,800	157,900
Deferred tax benefit	(800)
Designated as Hedging Instrument \| Interest Rate Swap
Derivative [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)		1,300	(800)
Deferred tax benefit	100
Designated as Hedging Instrument \| Cash Flow Hedging
Derivative [Line Items]
Gain (loss) on cash flow hedge in earnings	6,500	8,600	2,700
Designated as Hedging Instrument \| Interest Rate Swap
Derivative [Line Items]
Number of interest rate swaps held \| swap					2
Derivative, Fixed Interest Rate					0.68%
Derivative, Notional Amount					$ 250,000
Not Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)	0
Non-designated foreign currency hedge contracts outstanding	45,800	72,900
Net Revenues Cost Of Goods Sold And Selling General And Administrative Expense [Member] \| Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)	12,249	$ 3,700	$ 5,100
Other income (expense), net \| Designated as Hedging Instrument \| Interest Rate Swap
Derivative [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)	$ (878)

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Designated as Hedging Instrument \| Foreign Exchange Contract \| Net revenues, COGS, and SG&A
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)	$ 12,249	$ 3,700	$ 5,100
Amount of Loss Reclassifiedfrom OCI into Earnings (Effective Portion)	6,464
Designated as Hedging Instrument \| Foreign Exchange Contract \| Interest income (expense), net
Derivative Instruments, Gain (Loss) [Line Items]
Amount Excluded from Effectiveness Testing	(170)
Designated as Hedging Instrument \| Interest Rate Swap
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)		$ 1,300	$ (800)
Amount Excluded from Effectiveness Testing	0
Designated as Hedging Instrument \| Interest Rate Swap \| Other income (expense), net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)	(878)
Amount of Loss Reclassifiedfrom OCI into Earnings (Effective Portion)	0
Not Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)	0
Amount of Loss Reclassifiedfrom OCI into Earnings (Effective Portion)	0
Not Designated as Hedging Instrument \| Foreign Exchange Contract \| Interest income (expense), net
Derivative Instruments, Gain (Loss) [Line Items]
Amount Excluded from Effectiveness Testing	$ 7,510

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets) (Details) - USD ($) $ in Thousands	Mar. 28, 2015	Mar. 29, 2014
Derivative Liabilities:
Derivative Liabilities	$ 2,657	$ 1,255
Designated as Hedging Instrument
Derivative Assets:
Derivative Assets	9,740	3,824
Derivative Liabilities:
Derivative Liabilities	2,658	1,255
Designated as Hedging Instrument \| Foreign Exchange Contract \| Other Current Assets
Derivative Assets:
Derivative Assets	9,740	2,574
Designated as Hedging Instrument \| Foreign Exchange Contract \| Other Current Liabilities
Derivative Liabilities:
Derivative Liabilities	2,499	1,255
Designated as Hedging Instrument \| Interest Rate Swap \| Other Current Assets
Derivative Assets:
Derivative Assets	0	1,250
Designated as Hedging Instrument \| Interest Rate Swap \| Other Current Liabilities
Derivative Liabilities:
Derivative Liabilities	$ 159	$ 0

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis) (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Mar. 28, 2015	Mar. 29, 2014
Assets
Money market funds	$ 119,946	$ 135,378
Foreign currency hedge contracts	9,740	2,574
Interest rate swap		1,250
Assets, Fair Value Disclosure, Total	129,686	139,202
Liabilities
Foreign currency hedge contracts	2,499	1,255
Interest rate swap	159	7,645
Contingent consideration	4,727
Liabilities, Fair Value Disclosure, Total	7,385	8,900
Quoted Market Prices for Identical Assets (Level 1)
Assets
Money market funds	119,946	135,378
Foreign currency hedge contracts	0	0
Interest rate swap		0
Assets, Fair Value Disclosure, Total	119,946	135,378
Liabilities
Foreign currency hedge contracts	0	0
Interest rate swap	0	0
Contingent consideration	0
Liabilities, Fair Value Disclosure, Total	0	0
Significant Other Observable Inputs (Level 2)
Assets
Money market funds	0	0
Foreign currency hedge contracts	9,740	2,574
Interest rate swap		1,250
Assets, Fair Value Disclosure, Total	9,740	3,824
Liabilities
Foreign currency hedge contracts	2,499	1,255
Interest rate swap	159	0
Contingent consideration	0
Liabilities, Fair Value Disclosure, Total	2,658	1,255
Significant Unobservable Inputs (Level 3)
Assets
Money market funds	0	0
Foreign currency hedge contracts	0	0
Interest rate swap		0
Assets, Fair Value Disclosure, Total	0	0
Liabilities
Foreign currency hedge contracts	0	0
Interest rate swap	0	7,645
Contingent consideration	4,727
Liabilities, Fair Value Disclosure, Total	$ 4,727	$ 7,645

NOTES PAYABLE AND LONG-TERM DEBT (Schedule of Notes Payable and Long-Term Debt) (Details) - USD ($) $ in Thousands	Mar. 28, 2015	Mar. 29, 2014
Debt Instrument [Line Items]
Long-term debt	$ 430,483
Less current portion	(21,522)	$ (45,630)
Long term debt	406,369	392,057
Term loan, net of financing fees
Debt Instrument [Line Items]
Long-term debt	426,814	435,338
Mortgage Obligation
Debt Instrument [Line Items]
Long-term debt	851	1,906
Bank loans and other borrowings
Debt Instrument [Line Items]
Long-term debt	$ 226	$ 443

NOTES PAYABLE AND LONG-TERM DEBT (Narrative) (Details) $ in Thousands			1 Months Ended	12 Months Ended
	Jun. 30, 2014 USD ($)	Aug. 01, 2012 USD ($)	Dec. 31, 2000 USD ($)	Mar. 28, 2015 USD ($)	Mar. 29, 2014 USD ($)	Mar. 30, 2013 USD ($)	Dec. 29, 2012	Dec. 02, 2000 USD ($)
Debt Instrument [Line Items]
Variable rate basis				LIBOR
Payments of Debt Issuance Costs				$ 1,013	$ 0	$ 5,467
Interest paid				8,497	8,942	$ 5,910
Interest payable				600
Long-term debt				430,483
Term Loan
Debt Instrument [Line Items]
Face amount of debt				429,400
Basis spread on variable rate		1.375%
Amount outstanding				379,400
Effective interest rate		2.00%
Deferred finance costs				5,500
Debt discount				(2,600)
Term Loan \| Pall Corporation [Member]
Debt Instrument [Line Items]
Face amount of debt		$ 475,000
Adjusted libor rounding percentage		6.25%
Term loan, net of financing fees
Debt Instrument [Line Items]
Long-term debt				$ 426,814	435,338
Revolving Credit Facility
Debt Instrument [Line Items]
Face amount of debt		$ 50,000
Term of debt				5 years
Maximum borrowing capacity	$ 100,000
Consolidated total leverage ratio				3.0
Consolidated interest coverage ratio				4.0
Commitment fee				0.25%
Long-term debt				$ 50,000
Revolving Credit Facility \| Minimum
Debt Instrument [Line Items]
Commitment fee				0.175%
Revolving Credit Facility \| Maximum
Debt Instrument [Line Items]
Commitment fee				0.30%
Credit Agreement
Debt Instrument [Line Items]
Variable rate basis				1-month USD-LIBOR-BBA
Adjusted libor rounding percentage							0.625%
Credit Agreement \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Effective interest rate				1.5625%
Credit Agreement \| London Interbank Offered Rate (LIBOR) [Member] \| Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	1.125%
Credit Agreement \| London Interbank Offered Rate (LIBOR) [Member] \| Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	1.50%
Mortgage Obligation
Debt Instrument [Line Items]
Face amount of debt								$ 10,000
Term of debt				180 months
Long-term debt				$ 851	$ 1,906
Monthly principal and interest payments			$ 100
Stated percentage								8.41%

NOTES PAYABLE AND LONG-TERM DEBT (Schedule of Notes Payable and Long-Term Debt Maturities) (Details) - USD ($) $ in Thousands	Mar. 28, 2015	Mar. 29, 2014
Debt Instrument [Line Items]
2015	$ 22,337
2016	42,748
2017	45,071
2018	151,763
2020	168,564
Long-term debt	430,483
Mortgage Obligation
Debt Instrument [Line Items]
2015	851
2016	0
2017	0
2018	0
2020	0
Long-term debt	851	$ 1,906
Credit Facilities
Debt Instrument [Line Items]
2015	21,342
2016	42,683
2017	45,054
2018	151,763
2020	168,564
Long-term debt	429,406
Bank loans and other borrowings
Debt Instrument [Line Items]
2015	144
2016	65
2017	17
2018	0
2020	0
Long-term debt	$ 226	$ 443

INCOME TAXES (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
INCOME TAXES (Narrative) (Details) - USD ($) $ in Thousands	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012
Income Taxes [Line Items]
Foregin source income	$ 48,430	$ 43,260	$ 32,537
Valuation allowance	8,524	2,400	$ 0
Tax credit carry-forward, net	8,678	$ 2,660
Undistributed foreign earnings of subsidiaries	$ 300,200
U.S. federal statutory income tax rate	35.00%	35.00%	35.00%
Unrecognized tax benefits	$ 7,070	$ 5,604	$ 6,930	$ 6,885
Unrecognized tax benefits that will impact effective tax rate	2,000	5,600	6,700
Unrecognized tax benefits, increases from closure of statute of limitations	1,500
Unrecognized tax positions possible change in the next twelve months	900
Accrued interest and penalties	700	800
Accrued interest on income tax benefit	300	$ 0	$ 100
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Valuation allowance	12,900
Operating loss carry-forwards	11,700
Tax credit carry-forward, net	6,400
Domestic Tax Authority [Member] \| Excess Stock Based Compensation
Income Taxes [Line Items]
Operating loss carry-forwards	1,500
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Operating loss carry-forwards	23,600
Tax credit carry-forward, net	4,000
State and Local Jurisdiction [Member] \| Excess Stock Based Compensation
Income Taxes [Line Items]
Operating loss carry-forwards	4,000
Foreign Tax Authority [Member]
Income Taxes [Line Items]
Operating loss carry-forwards	$ 6,600
Switzerland
Income Taxes [Line Items]
Tax holiday term	10 years

INCOME TAXES (Schedule Domestic and Foreign Income Before Provision for Income Tax) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Income Tax Disclosure [Abstract]
Domestic	$ (17,265)	$ (6,859)	$ 17,360
Foreign	48,430	43,260	32,537
Income before provision for income taxes	$ 31,165	$ 36,401	$ 49,897

INCOME TAXES (Schedule of Income Tax Provision Components) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Current
Federal	$ 3,526	$ (4,896)	$ 3,795
State	898	873	1,324
Foreign	5,614	5,478	5,389
Total current	10,038	1,455	10,508
Deferred
Federal	1,227	(1,785)	1,644
State	3,215	207	(229)
Foreign	(212)	1,376	(826)
Total deferred	4,230	(202)	589
Total	$ 14,268	$ 1,253	$ 11,097

INCOME TAXES (Schedule of Net Deferred Tax Asset) (Details) - USD ($) $ in Thousands	Mar. 28, 2015	Mar. 29, 2014
Income Tax Disclosure [Abstract]
Depreciation	$ (23,733)	$ (23,658)
Amortization	(24,038)	(18,618)
Inventory	6,189	7,371
Hedging	84	321
Accruals, reserves and other	15,927	10,368
Net operating loss carry-forward	5,392	1,507
Stock based compensation	10,652	8,757
Tax credit carry-forward, net	8,678	2,660
Gross deferred taxes	(849)	(11,292)
Less valuation allowance	(16,027)	(3,083)
Net deferred tax liability	$ (16,876)	$ (14,375)

INCOME TAXES (Schedule of Effective Income Tax Rate Reconciliation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Income Tax Disclosure [Abstract]
Tax at federal statutory rate	$ 10,907	$ 12,739	$ 17,464
Tax at federal statutory rate	35.00%	35.00%	35.00%
Domestic manufacturing deduction	$ 0	$ 0	$ (504)
Domestic manufacturing deduction	(0.00%)	(0.00%)	(1.00%)
Difference between U.S. and foreign tax	$ (6,929)	$ (10,846)	$ (5,584)
Difference between U.S. and foreign tax	(22.20%)	(29.80%)	(11.20%)
State income taxes net of federal benefit	$ (818)	$ (252)	$ 718
State income taxes net of federal benefit	(2.60%)	(0.70%)	1.40%
Change in uncertain tax positions	$ (1,762)	$ (1,678)	$ (580)
Change in uncertain tax positions	(5.70%)	(4.60%)	(1.20%)
Intercompany loan deduction	$ 0	$ (2,185)	$ 0
Intercompany loan deduction	(0.00%)	(6.00%)	(0.00%)
Non-deductible expenses	$ 1,237	$ 1,035	$ 1,178
Non-deductible expenses	4.00%	2.80%	2.40%
Research credits	$ (1,000)	$ (688)	$ (799)
Research credits	(3.20%)	(1.90%)	(1.60%)
Naked Credit	$ 3,826	$ 0	$ 0
Naked Credit	12.30%	0.00%	0.00%
Valuation allowance	$ 8,524	$ 2,400	$ 0
Valuation allowance	27.40%	6.60%	0.00%
Other, net	$ 283	$ 728	$ (796)
Other, net	0.80%	2.00%	(1.60%)
Total	$ 14,268	$ 1,253	$ 11,097
Income tax provision	45.80%	3.40%	22.20%

INCOME TAXES (Summary of Gross Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning Balance	$ 5,604	$ 6,930	$ 6,885
Additions based upon positions related to the current year	0	0	1,192
Additions for tax positions of prior years	3,234	990	18
Settlements with taxing authorities	(338)	0	(80)
Closure of statute of limitations	(1,430)	(2,316)	(1,085)
Ending Balance	$ 7,070	$ 5,604	$ 6,930

COMMITMENTS AND CONTINGENCIES (Schedule of Approximate Future Basic Rental Commitments under Operating Leases) (Details) $ in Thousands	Mar. 28, 2015 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2016	$ 6,797
2017	4,780
2018	3,758
2019	2,427
2020 and thereafter	11,585
Operating Leases, Future Minimum Payments Due	$ 29,347

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 29, 2014	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Loss Contingencies [Line Items]
Rent expense		$ 6.3	$ 7.7	$ 7.0
Italian Employment Litigation
Loss Contingencies [Line Items]
Damages sought	$ 3.7

CAPITAL STOCK (Narrative) (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 28, 2015 USD ($) times Members individual PurchasePeriods $ / shares shares	Mar. 29, 2014 USD ($) $ / shares shares	Mar. 30, 2013 USD ($) $ / shares	Oct. 22, 2014 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense \| $	$ 14,095	$ 13,081	$ 10,969
Stock-based compensation expense recognized \| $		13,100	11,000
Income tax benefit recognized related to stock-based compensation \| $	4,500	4,300	3,500
Excess tax benefit on exercise of stock options \| $	$ 1,569	$ 2,395	4,101
Performance shares target, percentage	100.00%
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)	3,761,666	3,834,372
Total intrinsic value of options exercised \| $	$ 5,600	$ 11,700	$ 20,900
Total unrecognized compensation cost related to non vested awards \| $	$ 9,200
Total unrecognized compensation cost related to non vested stock options, weighted average period of recognition (in years)	2 years 4 months 13 days
Weighted average grant date fair value of options granted (in dollars per share) \| $ / shares	$ 7.91	$ 10.15	$ 9.76
Annual unvested stock option forfeiture rate (as a percent)	8.00%	8.00%
Market Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity instruments other than options outstanding (in shares)	287,682
Total unrecognized compensation cost related to non vested awards \| $	$ 11,200
Weighted Average Market Value at Grant Date (in dollars per share), Beginning Balance \| $ / shares	$ 37.42
Performance Share Units (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for award (in shares)	863,046
Weighted Average Market Value at Grant Date (in dollars per share), Awarded \| $ / shares	$ 85
Stock compensation expense \| $	$ 662
Total unrecognized compensation cost related to non vested awards \| $	$ 3,869
Number of senior executives \| individual	14
Performance Shares Threshold \| $ / shares	$ 50
Performance Shares Received Below Threshold	0
Performance Shares Target Multiplier \| times	3
Weighted Average Market Value at Grant Date (in dollars per share), Beginning Balance \| $ / shares				$ 35.09
Target Shares (in shares)	129,130
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost related to non vested awards \| $	$ 13,200
Total unrecognized compensation cost related to non vested stock options, weighted average period of recognition (in years)	2 years 4 months 13 days
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance shares target, percentage	0.00%
Minimum \| Performance Share Units (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target Shares (in shares)	0
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance shares target, percentage	200.00%
Maximum \| Performance Share Units (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target Shares (in shares)	258,260
Long-term Incentive Plan 2000 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for award (in shares)	7,000,000
Long-term Incentive Plan 2000 [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for grant (in shares)	0
Options outstanding (in shares)	55,750
Incentive Compensation Plan 2005 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of members on board of directors (in board members) \| Members	3
Maximum number of shares available for award (in shares)	15,024,920
Maximum number of shares available for grant (in shares)	999,243
Number of equity instruments other than options counted against maximum number of award shares for every share granted (in shares)	3.26
Maximum number of years from grant date that options expire (in years)	7 years
Incentive Compensation Plan 2005 [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for award (in shares)	500,000
Number of options counted against maximum number of award shares for every share option issued (in shares)	1
Incentive Compensation Plan 2005 [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period in which awards become exercisable for employees (in years)	4 years
Period after grant that awards become exercisable for non-employee directors (in years)	1 year
Equity instruments other than options outstanding (in shares)	357,547
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for award (in shares)	1,400,000
Number of purchase periods (in purchase periods) \| PurchasePeriods	2
Percentage of purchase price for shares of common stock at fair market value (as a percent)	85.00%
Weighted average grant date fair value of the six-month option inherent in the Purchase Plan (in dollars per share) \| $ / shares	$ 7.09	$ 8.25	$ 8.50
Employee Stock Purchase Plan [Member] \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares purchased through payroll deductions (as a percent)	2.00%
Employee Stock Purchase Plan [Member] \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares purchased through payroll deductions (as a percent)	15.00%

CAPITAL STOCK (Schedule of Summary of Stock Option Activity) (Details) - Stock Options [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options Outstanding, (in shares), Beginning Balance	3,834,372
Options Outstanding, (in shares), Granted	592,024
Options Outstanding, (in shares), Exercised	(500,103)
Options Outstanding, (in shares), Forfeited	(164,627)
Options Outstanding, (in shares), Ending Balance	3,761,666	3,834,372
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted Average Exercise Price (in dollars per share), Beginning Balance	$ 32.93
Weighted Average Exercise Price (in dollars per share), Granted	34.87
Weighted Average Exercise Price (in dollars per share), Exercised	26.14
Weighted Average Exercise Price (in dollars per share), Forfeited	38.13
Weighted Average Exercise Price (in dollars per share), Ending Balance	$ 33.90	$ 32.93
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	4 years 7 days	4 years 2 months 9 days
Aggregate Intrinsic Value, Beginning Balance	$ 9,436
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	4 years 7 days	4 years 2 months 9 days
Aggregate Intrinsic Value, Ending Balance	$ 37,067	$ 9,436
Options Outstanding, (in shares), Exercisable and End of Period	2,281,022
Weighted Average Exercise Price (in dollars per share), Exercisable at End of Period	$ 31.57
Weighted Average Remaining Life, Exercisable at End of Period	2 years 11 months 1 day
Aggregate Intrinsic Value, Exercisable at End of Period	$ 27,826
Options Outstanding, (in shares), Vested and Expected to Vest at End of Period	3,596,493
Weighted Average Exercise Price (in dollars per share), Vested or Expected to Vest at End of Period	$ 33.73
Weighted Average Remaining Life, Vested or Expected to Vest at End of Period	3 years 11 months 5 days
Aggregate Intrinsic Value, Vested and Expected to Vest at End of Period	$ 36,066

CAPITAL STOCK (Schedule of Assumptions Used to Estimate Fair Value) (Details)	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend Yield	0.00%
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	23.70%	22.90%	24.90%
Expected term	6 months	6 months	6 months
Risk-free interest rate	0.10%	0.10%	0.20%
Dividend Yield	0.00%	0.00%	0.00%
Market Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	20.00%
Expected term	3 years 8 months 12 days
Risk-free interest rate	0.90%
Performance Share Units (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	20.00%
Expected term	3 years
Risk-free interest rate	0.78%
Dividend history	12 months
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	22.50%	24.80%	26.40%
Expected term	4 years 10 months 24 days	4 years 10 months 24 days	4 years 10 months 24 days
Risk-free interest rate	1.50%	1.30%	0.80%
Dividend Yield	0.00%	0.00%	0.00%

CAPITAL STOCK (Schedule of Summary of Performance, Restricted, and Market Stock Units Activity) (Details) - Performance, Restricted and Market Stock Units [Member]	12 Months Ended
	Mar. 28, 2015 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Shares, Beginning Balance \| shares	599,673
Shares, Awarded \| shares	351,666
Shares, Released \| shares	(110,048)
Shares, Forfeited \| shares	(66,932)
Shares, Ending Balance \| shares	774,359
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Weighted Average Market Value at Grant Date (in dollars per share), Beginning Balance \| $ / shares	$ 37.70
Weighted Average Market Value at Grant Date (in dollars per share), Awarded \| $ / shares	35.18
Weighted Average Market Value at Grant Date (in dollars per share), Released \| $ / shares	36.65
Weighted Average Market Value at Grant Date (in dollars per share), Forfeited \| $ / shares	37.83
Weighted Average Market Value at Grant Date (in dollars per share), Ending Balance \| $ / shares	$ 36.70

EARNINGS PER SHARE ("EPS") (Schedule of Earnings Per Share Reconciliation) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 28, 2015	Dec. 27, 2014	Sep. 27, 2014	Jun. 28, 2014	Mar. 29, 2014	Dec. 28, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Basic EPS
Net income	$ (2,929)	$ 15,988	$ 7,487	$ (3,649)	$ 10,184	$ 16,290	$ 16,548	$ (7,874)	$ 16,897	$ 35,148	$ 38,800
Basic weighted average shares (in shares)									51,533	51,611	51,349
Basic income per share (in dollars per share)	$ (0.06)	$ 0.31	$ 0.15	$ (0.07)	$ 0.20	$ 0.31	$ 0.32	$ (0.15)	$ 0.33	$ 0.68	$ 0.76
Diluted EPS
Net income	$ (2,929)	$ 15,988	$ 7,487	$ (3,649)	$ 10,184	$ 16,290	$ 16,548	$ (7,874)	$ 16,897	$ 35,148	$ 38,800
Basic weighted average shares (in shares)									51,533	51,611	51,349
Net effect of common stock equivalents (in shares)									556	766	910
Diluted weighted average shares (in shares)									52,089	52,377	52,259
Diluted income per share (in dollars per share)	$ (0.06)	$ 0.31	$ 0.14	$ (0.07)	$ 0.19	$ 0.31	$ 0.32	$ (0.15)	$ 0.32	$ 0.67	$ 0.74
Stock options excluded from computation of weighted average shares outstanding (in shares)									1,600	1,100	500

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Property, Plant and Equipment [Line Items]
Total	$ 731,762	$ 701,855
Less: accumulated depreciation and amortization	409,814	430,418
Net property, plant and equipment	321,948	271,437
Depreciation expense	52,600	52,600	$ 43,400
Land
Property, Plant and Equipment [Line Items]
Total	9,468	7,168
Building and building improvements
Property, Plant and Equipment [Line Items]
Total	118,384	83,439
Plant equipment and machinery
Property, Plant and Equipment [Line Items]
Total	220,793	236,539
Office equipment and information technology
Property, Plant and Equipment [Line Items]
Total	118,810	111,925
Haemonetics equipment
Property, Plant and Equipment [Line Items]
Total	$ 264,307	$ 262,784

RETIREMENT PLANS (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Benefit obligation, plan funded by company	$ 9,200	$ 7,400
Benefit obligation	(40,567)	(32,621)	$ (30,126)
Accumulated benefit obligation	34,900	30,900
Fair value of plan assets	23,165	19,981	19,577
Amount expected to be amortized from accumulated other comprehensive loss in next fiscal year	600
Subsidiaries [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Company contributions	1,000	800	2,400
Savings Plus Plan [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Company contributions	$ 5,800	$ 6,200	$ 4,900

RETIREMENT PLANS (Schedule of Components of Net Periodic Benefit Costs of Defined Benefit Pension Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Compensation and Retirement Disclosure [Abstract]
Service cost	$ 2,979	$ 3,351	$ 2,759
Interest cost on benefit obligation	686	623	639
Expected (return)/loss on plan assets	(449)	(435)	(413)
Actuarial loss/(gain)	107	88	196
Amortization of unrecognized prior service cost	(29)	182	(14)
Amortization of unrecognized transition obligation	45	47	48
Totals	$ 3,339	$ 3,856	$ 3,215

RETIREMENT PLANS (Schedule of Activity Under Defined Benefit Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Change in Benefit Obligation:
Benefit Obligation, beginning of year	$ (32,621)	$ (30,126)
Service cost	(2,979)	(3,351)	$ (2,759)
Interest cost	(686)	(623)	(639)
Benefits paid	4,902	4,474
Actuarial (loss)/gain	(6,883)	55
Employee and plan participants contribution	(2,978)	(2,963)
Plan Amendments	114	419
Foreign currency changes	564	(506)
Benefit obligation, end of year	(40,567)	(32,621)	(30,126)
Change in Plan Assets:
Fair value of plan assets, beginning of year	19,981	19,577
Company contributions	2,112	2,241
Benefits paid	(4,621)	(4,641)
Gain/(Loss) on plan assets	506	100
Employee and plan participants contributions	2,851	3,087
Employee and plan participants contributions	2,978	2,963
Foreign currency changes	2,336	(383)
Fair value of Plan Assets, end of year	23,165	19,981	$ 19,577
Funded Status	(17,402)	(12,640)
Unrecognized net actuarial loss/(gain)	11,096	5,899
Unrecognized initial obligation	64	94
Unrecognized prior service cost	(459)	(422)
Net amount recognized	$ (6,701)	$ (7,069)

RETIREMENT PLANS (Schedule of Components of Change Recorded in Accumulated Other Comprehensive Income Related to Defined Benefit Plans, Net of Tax) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Components of Change Recorded in Accumulated Other Comprehensive Income Related to Defined Benefit Plans, Net of Tax [Roll Forward]
Impact of Defined Benefit Plans, Net of Tax, Balance	$ (4,592)	$ (5,073)	$ (4,253)
Obligation at transition	(19)	172	556
Actuarial loss	(6,198)	(129)	(1,237)
Prior service cost	1,886	438	(139)
Impact of Defined Benefit Plans, Net of Tax, Balance	$ (8,923)	$ (4,592)	$ (5,073)

RETIREMENT PLANS (Schedule of Weighted Average Rates Used to Determine Net Periodic Benefit Costs) (Details)	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Compensation and Retirement Disclosure [Abstract]
Discount rate	0.93%	2.02%	1.97%
Rate of increased salary levels	1.65%	1.57%	1.42%
Expected long-term rate of return on assets	1.68%	1.94%	1.92%

RETIREMENT PLANS (Schedule of Estimated Future Benefit Payments) (Details) $ in Thousands	Mar. 28, 2015 USD ($)
Expected Benefit Payments
Fiscal Year 2016	$ 1,735
Fiscal Year 2017	1,654
Fiscal Year 2018	1,502
Fiscal Year 2019	1,610
Fiscal Year 2020	1,732
Fiscal Year 2021-2024	$ 7,493

SEGMENT INFORMATION (Revenues from External Customers) (Details) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 28, 2015 USD ($)	Dec. 27, 2014 USD ($)	Sep. 27, 2014 USD ($)	Jun. 28, 2014 USD ($)	Mar. 29, 2014 USD ($)	Dec. 28, 2013 USD ($)	Sep. 28, 2013 USD ($)	Jun. 29, 2013 USD ($)	Mar. 28, 2015 USD ($) segment	Mar. 29, 2014 USD ($)	Mar. 30, 2013 USD ($)
Segment Reporting [Abstract]
Number of Operating Segments \| segment									4
Revenue from External Customer [Line Items]
Total revenues	$ 226,478	$ 231,827	$ 227,580	$ 224,488	$ 241,091	$ 242,120	$ 235,755	$ 219,543	$ 910,373	$ 938,509	$ 891,990
Plasma disposables
Revenue from External Customer [Line Items]
Total revenues									319,190	291,895	268,900
Blood center disposables
Revenue from External Customer [Line Items]
Total revenues									339,193	389,719	357,771
Platelet
Revenue from External Customer [Line Items]
Total revenues									152,588	156,643	169,602
Red cell
Revenue from External Customer [Line Items]
Total revenues									42,700	42,378	49,733
Whole blood
Revenue from External Customer [Line Items]
Total revenues									143,905	190,698	138,436
Hospital disposables
Revenue from External Customer [Line Items]
Total revenues									125,043	125,220	131,094
Surgical
Revenue from External Customer [Line Items]
Total revenues									62,540	66,876	73,508
OrthoPAT
Revenue from External Customer [Line Items]
Total revenues									20,316	25,042	30,230
Diagnostics
Revenue from External Customer [Line Items]
Total revenues									42,187	33,302	27,356
Disposables revenue
Revenue from External Customer [Line Items]
Total revenues									783,426	806,834	757,765
Software solutions
Revenue from External Customer [Line Items]
Total revenues									72,185	70,441	69,952
Equipment & other
Revenue from External Customer [Line Items]
Total revenues									$ 54,762	$ 61,234	$ 64,273

SEGMENT INFORMATION (Enterprise Wide Disclosures about Product and Services) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	$ 910,373	$ 938,509	$ 891,990
Total Assets	1,485,417	1,514,178	1,461,917
Long-Lived Assets	915,140	891,202	851,815
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	494,788	500,719	454,874
Total Assets	810,159	810,409	830,754
Long-Lived Assets	532,187	519,396	503,606
Other North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	9,617	9,557	6,851
Total Assets	240,610	225,998	225,849
Long-Lived Assets	212,548	211,624	209,439
Total North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	504,405	510,276	461,725
Total Assets	1,050,769	1,036,407	1,056,603
Long-Lived Assets	744,735	731,020	713,045
Japan
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	88,298	108,679	120,726
Total Assets	41,621	53,207	44,189
Long-Lived Assets	9,230	11,522	12,977
Other Asia
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	102,095	94,762	84,860
Total Assets	79,084	53,055	41,037
Long-Lived Assets	46,857	17,269	8,076
Total Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	215,575	224,792	224,679
Total Assets	313,943	371,509	320,088
Long-Lived Assets	$ 114,318	$ 131,391	$ 117,717

RESTRUCTURING (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Restructuring and Related Activities [Abstract]
Expected cost	$ 45,000
Expected cost in cash	27,000
Restructuring charges incurred	36,863	$ 49,051	$ 10,892
Restructuring charges in next twelve months	13,300
Transformation costs	29,916	35,700	61,565
Payments	$ (42,265)	$ (25,372)	$ (5,377)

RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 23,636	$ 3,262	$ 1,994
Cost Incurred	36,863	49,051	10,892
Payments	(42,265)	(25,372)	(5,377)
Asset Write down	(1,622)	(3,305)	(4,247)
Ending Balance	16,612	23,636	3,262
Transformation costs	29,916	35,700	61,565
Total restructuring and transformation	66,779	84,751	72,457
Integration and other costs
Restructuring Reserve [Roll Forward]
Transformation costs	24,061	30,701	60,878
Accelerated depreciation
Restructuring Reserve [Roll Forward]
Transformation costs	930	4,203	687
Asset disposal
Restructuring Reserve [Roll Forward]
Transformation costs	4,925	796	0
Severance and other employee costs
Restructuring Reserve [Roll Forward]
Beginning Balance	22,908	3,089	1,461
Cost Incurred	19,879	31,492	6,214
Payments	(26,394)	(11,673)	(4,586)
Asset Write down	0	0	0
Ending Balance	16,393	22,908	3,089
Other costs
Restructuring Reserve [Roll Forward]
Beginning Balance	728	173
Cost Incurred	15,362	14,254	431
Payments	(15,871)	(13,699)
Asset Write down	0	0
Ending Balance	219	728	173
Accelerated depreciation
Restructuring Reserve [Roll Forward]
Beginning Balance	0	0
Cost Incurred	1,326	2,390	0
Payments	0	0
Asset Write down	(1,326)	(2,390)
Ending Balance	0	0	0
Facility-related costs
Restructuring Reserve [Roll Forward]
Beginning Balance		173	533
Cost Incurred			431
Payments			(791)
Asset Write down			0
Ending Balance			173
Asset write-down
Restructuring Reserve [Roll Forward]
Beginning Balance	0	0	0
Cost Incurred	296	915	4,247
Payments	0		0
Asset Write down	(296)	(915)	(4,247)
Ending Balance	0	0	0
Asset disposal
Restructuring Reserve [Roll Forward]
Cost Incurred	$ 296	$ 915	$ 4,247

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Capitalization of Software and Development Costs [Abstract]
Capitalized software development costs for ongoing initiatives	$ 9.5	$ 6.0
Software costs capitalized, net	39.7	31.7
Total costs capitalized related to in process software development initiatives	7.9	15.6
Interest costs capitalized	0.2	0.4
Capitalized costs amortized (placed into service)	15.7	10.4
Amortization of capitalized software development cost expense	$ 3.2	$ 1.1	$ 0.9

SUMMARY OF QUARTERLY DATA (UNAUDITED) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 28, 2015	Dec. 27, 2014	Sep. 27, 2014	Jun. 28, 2014	Mar. 29, 2014	Dec. 28, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Quarterly Financial Data [Abstract]
Net revenues	$ 226,478	$ 231,827	$ 227,580	$ 224,488	$ 241,091	$ 242,120	$ 235,755	$ 219,543	$ 910,373	$ 938,509	$ 891,990
Gross profit	108,365	111,661	108,114	106,278	115,440	121,629	119,884	111,412	434,418	468,365	428,131
Operating (loss) income	11,539	18,260	12,407	(1,666)	12,366	17,554	23,120	(6,608)	40,540	46,432	56,437
Net (loss) income	$ (2,929)	$ 15,988	$ 7,487	$ (3,649)	$ 10,184	$ 16,290	$ 16,548	$ (7,874)	$ 16,897	$ 35,148	$ 38,800
Per share data:
Basic income per share (in dollars per share)	$ (0.06)	$ 0.31	$ 0.15	$ (0.07)	$ 0.20	$ 0.31	$ 0.32	$ (0.15)	$ 0.33	$ 0.68	$ 0.76
Diluted income per share (in dollars per share)	$ (0.06)	$ 0.31	$ 0.14	$ (0.07)	$ 0.19	$ 0.31	$ 0.32	$ (0.15)	$ 0.32	$ 0.67	$ 0.74

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

ACCUMULATED OTHER COMPREHENSIVE INCOME (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income, Balance	$ 1,410	$ 5,433
Other comprehensive income before reclassifications	(16,749)	4,289
Amounts reclassified from Accumulated Other Comprehensive Income	(6,385)	(8,312)
Other comprehensive loss	(23,134)	(4,023)	$ (3,677)
Accumulated Other Comprehensive Income, Balance	(21,724)	1,410	5,433
Foreign currency
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income, Balance	3,198	4,133
Other comprehensive income before reclassifications	(23,710)	(935)
Amounts reclassified from Accumulated Other Comprehensive Income	0	0
Other comprehensive loss	(23,710)	(935)
Accumulated Other Comprehensive Income, Balance	(20,512)	3,198	4,133
Defined benefit plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income, Balance	(4,592)	(5,073)
Other comprehensive income before reclassifications	(4,410)	223
Amounts reclassified from Accumulated Other Comprehensive Income	79	258
Other comprehensive loss	(4,331)	481
Accumulated Other Comprehensive Income, Balance	(8,923)	(4,592)	(5,073)
Net Unrealized Gain/loss on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income, Balance	2,804	6,373
Other comprehensive income before reclassifications	11,371	5,001
Amounts reclassified from Accumulated Other Comprehensive Income	(6,464)	(8,570)
Other comprehensive loss	4,907	(3,569)
Accumulated Other Comprehensive Income, Balance	$ 7,711	$ 2,804	$ 6,373

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References + Details

ACCUMULATED OTHER COMPREHENSIVE INCOME (Details 2) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 28, 2015	Dec. 27, 2014	Sep. 27, 2014	Jun. 28, 2014	Mar. 29, 2014	Dec. 28, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Realized net gain on derivatives									$ (9,375)	$ (10,031)	$ (6,540)
Income tax effect									(14,268)	(1,253)	(11,097)
Net income	$ (2,929)	$ 15,988	$ 7,487	$ (3,649)	$ 10,184	$ 16,290	$ 16,548	$ (7,874)	16,897	35,148	$ 38,800
Net Unrealized Gain/loss on Derivatives \| Amounts Reclassified from Other Comprehensive Income
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Realized net gain on derivatives									6,736	8,960
Income tax effect									(272)	(390)
Net income									6,464	8,570
Defined benefit plans \| Amounts Reclassified from Other Comprehensive Income
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Realized net gain on derivatives									123	317
Income tax effect									(44)	(59)
Net income									$ 79	$ 258

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

VALUATION AND QUALIFYING ACCOUNTS (Details) - Allowance for Doubtful Accounts - USD ($) $ in Thousands	12 Months Ended
	Mar. 28, 2015	Mar. 29, 2014	Mar. 30, 2013
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Fiscal Year	$ 1,676	$ 1,727	$ 1,480
Charged to Costs and Expenses	399	186	446
Write-Offs (Net of Recoveries)	(326)	(237)	(199)
Balance at End of Fiscal Year	$ 1,749	$ 1,676	$ 1,727